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ABSTRACT 
The disease burden caused by respiratory infections in the human infant is greater 
than any other disease. Human influenza and respiratory syncytial viruses are two 
major causes of respiratory infections in infant and young children and often augment 
the development of subsequent bacterial infections. Prevention and treatment 
strategies for infant respiratory disease are constrained by the lack of effective 
vaccines, especially against respiratory viruses, and increasing antibiotic resistance. 
Breast-feeding is widely reported to help protect infants against infectious disease. 
Some of this protective activity is clearly due to the immune component of breast 
milk; however, the non-immune component, especially human milk oligosaccharides 
(HMO) are also thought contribute to antimicrobial activity. Human milk contains a 
large variety of oligosaccharides, some of which are present in sufficient 
concentration to potentially function as receptor decoys for respiratory pathogens. To 
begin to define which of these human milk oligosaccharides (HMO) may possess 
antiviral activity, as well as to probe whether such HMO could enhance value as a 
nutriceutical when added to commercial infant formula, we have developed in vitro 
virus infectivity inhibition assays to screen selected HMO, as well as infant formulas 
and human milk for anti-influenza virus (H1N1) activity. The results of these 
screening assays demonstrated that selected HMO were able to block virus infectivity 
but only at relatively high HMO concentration. The inhibitory concentration 
necessary to achieve 50% inhibition of infectivity was ~10 mg/ml for all HMO tested 
with the exception of 3-fucosyllactose (~5 mg/ml); a concentration likely far 
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exceeding what would be feasible for use as a nutriceutical component of infant 
formula. Interestingly, in control experiments using various proprietary infant formula 
preparations, we discovered some of these formula contained relatively potent 
endogenous anti-H1N1 activities. One of these, XPE, exhibited dose dependent 
inhibition of both influenza A (H1N1) and human parainfluenza virus (HPIV-3) 
infectivity. The XPE inhibitory activity was purified by organic solvent extraction and 
semi-preparative high-performance thin-layer chromatography. Furthermore, a similar 
antiviral activity also was extracted and partially purified from human milk.  These 
results indicate that a lipid or a lipid-like component is at least partially responsible 
for the observed antiviral activity of human milk and certain infant formula.  These 
results also suggest the lipid component of infant formula and human milk (HML), 
and perhaps other natural products are worthy of further exploration as a source of 
antiviral nutriceuticals. The use of such nutriceuticals, either alone or in combination 
with other bioactive natural products such as HMO, for the possible prevention and 
treatment of viral respiratory infection and disease in the human infant, is discussed. 
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CHAPTER 1: INTRODUCTION 
Respiratory viruses, including influenza virus, are the most common cause of 
respiratory tract disease in infants and young children and are a major public health 
problem in this age group. The nursing infant is particularly vulnerable to 
environmental pathogens due to the immaturity of its immune system. Although some 
progress has been made toward vaccine development during the past decades, the 
application of vaccines against influenza virus is hampered by the antigenic drift and 
antigenic shift seen in influenza viruses. Furthermore, current vaccines against 
respiratory syncytial virus (RSV) have no significant effect on preventing respiratory 
syncytial virus disease (Simoes, Tan, Ohlsson, Sales, & Wang, 2001). In addition, 
antibiotics are often prescribed for patients with lower respiratory tract infections, but 
the increasing emergence of antimicrobial resistance in bacterial pathogens 
threatening their continued effectiveness. Effective therapeutic or prophylactic agents 
without side effect are urgently needed for reducing the respiratory disease burden in 
infants and young children.  
 
The results of considerable research over many years have demonstrated the benefits 
of breastfeeding and the antimicrobial effects of human milk (C. E. Isaacs, 2011; 
McVEAGH & MILLER, 1997; Newburg, 1996). Besides immunological components, 
there are many non-immunological factors in human milk, which are considered to be 
anti-infective agents for infants, including oligosaccharides and lipids (Espinosa, 
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Tamez, & Prieto, 2007; C. E. Isaacs, Thormar, & Pessolano, 1986). It is generally 
believed that human milk oligosaccharides act as soluble receptor analogs that inhibit 
the attachment of pathogenic bacteria, viruses, and bacterial toxins to the mucosa of 
the infant colon and respiratory tract (Urashima et al., 2009). Some reports show that 
monoglycerides and free fatty acids produced from human milk lipolysis possess 
strong antiviral activity against enveloped viruses, regardless of whether the virus is a 
DNA or RNA virus (C. E. Isaacs, 2011).  These non-immunological, anti-infective 
factors are receiving more and more attention because of their potential nutriceutical, 
nonimmunogenic and nontoxic characteristic.   
 
The overarching hypothesis of the research presented here is that natural, non-immune 
components of human milk, such as HMO or HML have the potential to act as 
antiviral nutriceutical compounds that can effectively inhibit respiratory viruses 
infection and disease. The approach was to develop an in vitro, virus infectivity- 
blocking assay for use in screening the antiviral activity of various HMO, commercial 
and proprietary infant formula, and human milk components. In this screening assay, 
putative antiviral components were incubated with virus, the mixture added to host 
tissue culture cells, and virus infectivity quantified using an immunocytochemical 
assay. Components displaying antiviral activity in this screening assay were then 
partially characterized as to their identity and cellular mechanism of action. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Respiratory viral disease of the human infant 
2.1.1 Introduction 
The human disease burden caused by respiratory infection is more serious than from 
any other disease (Mizgerd, 2006). According the World Health Organization, there 
is18% mortality for young children below the age of five caused by respiratory 
disease; diarrheal disease (15%) and malaria (11%) were the next greatest killers 
among young children (World Health Organization, 2005). Besides the increased 
mortality, respiratory infection also accounts for increased morbidity in young 
children. Clinical reports indicate 22%of all children hospitalizations (Nicholson et al., 
2006) and 59% of general consultations (Olszewska, Zambon, & Openshaw, 2002) 
are the result of respiratory viral infection. Respiratory tract infections in the young 
also cause a large burden on national healthcare budgets (Nicholson et al., 2006).  
Every year 3% of all children less than 1 year old are admitted to the hospital with 
respiratory infections (D. K. Shay, Holman, Newman, Liu, Stout, & Anderson, 1999) 
and of these, viruses are the most common cause of both upper and lower respiratory 
tract disease in infants and young children.  
2.1.2 Infectious agents 
In temperate climates, most respiratory viruses infections usually occur in the winter. 
Disease peaks occur in January and February in the United States. Acute respiratory 
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tract infections, especially those resulting from influenza virus, respiratory syncytial 
virus and human parainfluenza virus contribute to a significant portion of medically 
attended illness and hospitalization of children younger than 5 years old (Figueras-
Aloy, Carbonell-Estrany, Quero, & IRIS, 2004; Harper et al., 2009). It is worth 
pointing out those complications secondary to viral-induced respiratory infection, 
such as otitis media, pulmonary disease, and secondary bacterial infections are not 
limited to high-risk children but also frequently affect otherwise healthy children (C. 
B. Hall et al., 2009; Mullins et al., 2004). Evidence provided by studies in the United 
States indicate more than 152 influenza-related deaths in children occurred during the 
2003-2004 influenza season, 47% of these children were previously healthy 
(Greenberg & Piedra, 2004). 
 
Respiratory syncytial virus is known as the primary causative agent of hospitalization 
in the first year of life for children in the world, and approximately100% of children 
in the United States are infected with the virus by age three. During the winter, RSV 
can infect up to 80% children less than two years of age (Leader & Kohlhase, 2002; 
Robert C., 1998; D. K. Shay, Holman, Newman, Liu, Stout, & Anderson, 1999c; 
Thompson et al., 2003). The disease caused by RSV infections is the most severe in 
premature infants and RSV has been reported to be the leading viral cause of infant 
death in this group (Thompson et al., 2003). Infants admitted to the hospital because 
of RSV infection usually need oxygen supplementation, mechanical ventilation and 
intensive care. There are several distinct disease syndromes that are associated with 
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RSV infections in children, including bronchiolitis, sudden infant death syndrome, 
childhood asthma, and post infection wheezing. Currently, there is no licensed 
available vaccine for RSV prevention (Hull, Thomson, & Kwiatkowski, 2000; 
Kneyber et al., 1998). 
 
The results of recent research have suggested that influenza virus infection in 
childhood also causes substantial medical and economic burden due to 
hospitalizations, medical visits, and antibiotic prescriptions in otherwise healthy 
children, especially those less than two years old.  Although RSV frequently causes 
more severe disease symptoms, the highest incidence of infection is caused by 
influenza virus (A. S. Monto, 2002). Although school age children who are infected 
with influenza virus usually do not require hospitalization, the high incidence of 
infection in these children results in them being the primary source of infection in a 
community. In children up to 4 years of age, the hospitalization rate is approximately 
100 per 100,000 children without high-risk medical conditions and approximately 500 
per 100,000 children with high-risk conditions. The morbidity and economic burden 
caused by influenza disease is evidenced by the fact that more than 25 million 
physician visits every year are caused by influenza viruses resulting in direct medical 
costs in the United States ranging from $1 to 3 billion (Couch, 2000; Patriarca, 1999). 
Complications of influenza in children include: acute otitis media, sinusitis, bronchitis, 
pneumonia, encephalitis, myositis, myocarditis, febrile seizures, encephalopathy and 
Reye's syndrome. As stated previously, school age children are the primary 
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transmission vectors in influenza epidemics, thus they are the main targets for 
immunization to prevent influenza spread in the general population (A. S. Monto & 
Sullivan, 1993; Andres, Donovan, Kuhlenschmidt, & Kuhlenschmidt, 2007) 
 
Other respiratory viruses contributing to the respiratory disease burden in children are 
the human metapneumoviruses and parainfluenza viruses. Human 
metapneumovirusesare responsible for 5-6% of respiratory disease in hospitalized 
children less than 5 years of age (van den Hoogen, Osterhaus, & Fouchier, 2004), 
whereas the parainfluenza viruses are second only to RSV increasing hospitalizations 
for lower respiratory tract infection in children less than 18 years old (Williams et al., 
2004). The clinical symptoms caused by the metapneumoviruses and parainfluenza 
viruses are similar to RSV (Williams et al., 2004). 
 
Adenoviruses are recognized as another important cause of acute respiratory 
infections in children, and are responsible for about 3-5% of the lower respiratory 
tract illnesses (Glezen et al., 1971). An adenovirus vaccine is available for military 
personnel, but it is not licensed for use in the general population. Other viruses, such 
as enteroviruses and rhinoviruses, are also responsible for the overall burden of 
respiratory disease during childhood (Greenberg & Piedra, 2004). Coronaviruses are 
believed as the cause of severe acute respiratory syndrome (SARS), which was first 
recognized in Hong Kong during the 2003 epidemic (Lee et al., 2003). SARS 
morbidity is higher than other respiratory viral disease, approximately one-fourth of 
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patients need intensive care and ventilation support. Compared to adults, SARS 
morbidity and mortality appear to be less severe in children. Mortality caused by 
SARS may range from 3 to 7% with good supportive care. Vaccines for SARS are in 
development but currently not available (Greenberg & Piedra, 2004). 
2.1.3 Upper respiratory tract infection 
Most respiratory virus infections in early childhood are limited to the upper 
respiratory tract, resulting in symptoms of the common cold, such as coryza, cough, 
and nasal congestion. Rhinitis and pharyngitis also are found frequently associated 
with upper respiratory infections as is conjunctivitis and tympanic vascular lesions. In 
some cases, otitis media occurs causing earache, tenderness of the tragus upon 
pressure, and a red bulging tympanic membrane upon inspection. Upper airway viral 
infection in infants is also often accompanied by fever and may cause lethargy or 
irritability and poor feeding. Symptoms caused by upper respiratory infection are 
usually mild, so specific treatment is usually not required. Antipyretics and nasal 
decongestants are often used to make feeding easier and reduce discomfort. 
2.1.4 Lower respiratory tract infection 
Approximately 33% of infants infected with respiratory virus can develop lower 
respiratory tract symptoms, including wheeze, severe cough, tachypnea, 
breathlessness, and respiratory distress. These symptoms cause clinical signs such as 
grunting, nasal flaring, and intercostal retractions, and rarely cyanosis. Auscultation of 
the chest reveals wheezes, crackles, crepitation, and inspiratory rhonchi or generally 
8 
reduced breath sounds that are caused by air trapping and peripheral hyperinflation of 
the lung (Tregoning & Schwarze, 2010). It is worth emphasizing that the recurrent 
episodes of apnea in RSV infection area serious threat to infants less than 6 months 
old (Darville & Yamauchi, 1998). 
 
Distinguishing between bronchitis, bronchiolitis, and pneumonia to define 
predominantly proximal airway disease, conducting airway disease, or involvement of 
the alveolar compartment, respectively, is a frequent method often used to classify 
respiratory illness.  The use of these classifications to make clinical diagnoses is 
controversial and lacks international acceptance, especially since the treatment is the 
much the same regardless of the classification (Tregoning & Schwarze, 2010). The 
strategy for treatment of lower respiratory tract infections (LRTI) are based on 
evaluation of the severity of respiratory damage by measuring the O2 saturation, blood 
gas values, and clinical evaluation of the severity of the respiratory distress (Adcock, 
Stout, Hauck, & Marshall, 1997). Other risk factors (e.g., crowding, gender, nutrition) 
and preexisting illness (e.g., chronic lung disease associated with prematurity) may 
also increase the severity of respiratory infections and thus influence strategies for 
disease management (Pavia, 2011). 
 
Extra pulmonary manifestations of LRTI in RSV infections are rarely observed. These 
manifestations include seizures, hyponatremia, cardiac arrhythmias, cardiac failure, 
and hepatitis (Eisenhut, 2006). While the epithelium is the primary site of infection 
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and viral replication, viral RNA not only has been found in the respiratory tract but 
also been transiently detected in peripheral blood mononuclear cells and, very rarely, 
in cardiac muscle and cerebrospinal fluid (Eisenhut, 2006). 
2.1.5 Bacterial co-infection 
An often-serious complication of respiratory viral illness is increased susceptibility to 
bacterial subsequent infection. This is most often seen in influenza but also has been 
reported for RSV infection (Rothberg, Haessler, & Brown, 2008a; Valarcher et al., 
2001). Evidences show that many of the deaths in the 1918-1919flu pandemic were 
due to secondary bacterial pneumonia (Klugman & Madhi, 2007).Viral infection 
facilitates bacterial infection through two mechanisms: compromising host physical 
barriers and altering the immune response. Studies have shown that viral infection and 
subsequent immune response may alter the respiratory epithelia, enhancing bacterial 
colonization and entry (Plotkowski, Puchelle, Beck, Jacquot, & Hannoun, 1986). For 
example, influenza virus can thin mucus and expose receptors on epithelial cells by 
the action of viral neuraminidase activity that is exploited for bacterial adhesion 
(Peltola, Murti, & McCullers, 2005). In addition, viral infection can suppress the 
innate immune response. Studies have shown that influenza virus infection can inhibit 
the initial neutrophil response thus increasing the risk for subsequent bacterial 
infection (Colamussi, White, Crouch, & Hartshorn, 1999; McCullers, Iverson, 
McKeon, & Murray, 2008; McNamee & Harmsen, 2006; van der Sluijs et al., 2006). 
Usually, bacterial co-infection occurs in the later stages of viral infection, after 
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dampening of the immune response has occurred. A crucial cytokine, IL-10, important 
in the resolution of the immune response, is increased in viral respiratory infections 
and may facilitate early dampening of the immune response and facilitate subsequent 
bacterial infection (van der Sluijs et al., 2004). A general down regulation of the host’s 
ability to detect pathogens, which is thought to happen following viral infection, also 
may increase the risk of intercurrent bacterial infection (Didierlaurent et al., 2008). As 
stated earlier, the incidence and consequence of bacterial co-infections in viral 
respiratory disease have resulted in significant increase in the use of prescription of 
antibiotics (Low, 2008). 
2.2 Influenza Virus 
Influenza viruses are a major cause of annual flu epidemics worldwide. In a typical 
year, approximately 15% of the U.S. population can be infected, leading to about 
36,000 deaths and more than 200,000 hospitalizations (Molinari et al., 2007). 
Influenza A viruses are enveloped, negative-sense, single-stranded RNA viruses of 
the Orthomyxoviridae family (Steinhauer & Skehel, 2002). The shape of influenza 
viruses is somewhat variable: ranging from spherical particles to more elongated oval 
forms, of 80–120 nm in diameter. Their genome contains eight RNA segments that 
encode for eleven viral proteins (Tumpey et al., 2004). Three of these proteins are 
present on the surface envelope of influenza viruses: hemagglutinin (HA), 
neuraminidase (NA), and matrix protein (M1). Other encoded proteins include 
nucleoprotein (NP), RNA polymerase subunits (PB1, PB2, PA), a pro-apoptotic PB1-
F2 protein, a proton-selective ion channel protein (M2) and nonstructural proteins 
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(NS1 and NS2) (Chen & Lander, 2001).  Among these proteins, HA and NA are the 
antigenic determinants of Influenza A viruses and the basis for their classification into 
different serotypes.  
 
Sixteen HA and nine NA serotypes have been identified thus far (Viswanathan et al., 
2010). The lack of a proofreading mechanism in Influenza virus’s polymerase leads to 
an error-prone process of transcription during virus. The selection and accumulation 
of these altered transcripts (mutations) is responsible for development of new 
Influenza A virus serotypes. This process, known as antigenic drift, helps the virus 
evade the host immune system by changing the HA, NA and M1 antigens exposed on 
the surface envelope. Furthermore, the segmented characteristic of viral RNA permits 
reassortment of genes between viruses of different serotypes and creation of a new 
virus subtypes. This process is known as antigenic shift. Both antigenic drift and 
antigenic shift are the principal mechanisms driving the evolution of influenza viruses 
(Nelson & Holmes, 2007). Antigenic drift is a continuous process and leads to gradual 
changes in surface antigens, while antigenic shift is an occasional occurrence and 
causes more immediate and significant changes in the virus antigenicity. 
2.2.1 Pathophysiology of Influenza virus 
Initial infection of respiratory tract with influenza viruses is likely due to direct nasal 
inoculation or inhalation of small particle-aerosols containing virus. Studies in 
volunteers have shown that virus delivered through aerosol route is at least 100-fold 
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more infectious than administrated by nasal drops (O'Donoghue, Ray, Terry, & Beaty, 
1973). It is still not well understand which mode of infection is predominant in nature. 
After initial infection, there is widespread involvement of the trachea, bronchi, and 
lower respiratory tract. Bronchoscopy with patients infected with typical, 
uncomplicated (non-pneumonic) acute influenza found diffuse inflammation of the 
larynx, trachea, and bronchi with mucosal injection and edema (Brady et al., 1990). 
Histological examination in these cases has revealed a range of histological findings 
from vacuolization of columnar cells with cell lose to extensive desquamation down 
to the basal layer of cells. Viral antigen can be detected in epithelial cells but is not 
found in the basal cell layer (Galbraith, Oxford, Schild, & Watson, 1969a; Galbraith, 
Oxford, Schild, & Watson, 1969).   
 
In general, the tissue response becomes more notable as one moves distally in the 
airway (Reuman et al., 1989). Epithelial compromise usually takes place with cellular 
infiltrates mainly composed of histiocytes and lymphocytes (Reuman et al., 1989). 
More severe cases investigated by autopsy show extensive necrotizing 
tracheobronchitis with ulceration and sloughing of the bronchial mucosa (Clover et al., 
1986; Galbraith, Oxford, Schild, & Watson, 1969). Recovery is associated by rapid 
regeneration of the epithelial cell layer and pseudometaplasia.  
 
Abnormal pulmonary functions are often seen in otherwise healthy, non-asthmatic 
young adults with uncomplicated acute influenza (Longini, Koopman, Monto, & Fox, 
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1982; Wingfield, Pollack, & Grunert, 1969). These pulmonary defects include 
diminished forced-flow rates; flow rates consistent with generalized increased 
resistance in airways less than 2 mm in diameter. Increased responses to 
bronchoprovocation (a diagnosis test of asthma) and increases in the alveolar-arterial 
oxygen gradient also have been seen (Knight, Fedson, Baldini, Douglas, & Couch, 
1970; Togo et al., 1970). Furthermore, pulmonary function defects can remain for 
several weeks after clinical recovery. Influenza in patients with chronic obstructive 
pulmonary disease or asthmatics may lead to acute declines in forced expiratory 
volume in 1 sec (FEV1) or forced vital capacity (FVC). Although, primary viral 
pneumonia is rarely seen as a severe complication of acute influenza (DIEFENBACH 
& WINTER, 1958; Rothberg, Haessler, & Brown, 2008), these patients have 
increased susceptibility to bronchoconstriction from air pollutants (e.g., nitrates) 
(Younkin, Betts, Roth, & Douglas, 1983). In patients where, viral infection of the 
lung has occurred, it is most often due to contiguous spread from the upper respiratory 
tract. In these patients, the disease is universally severe and is manifested by tracheitis, 
bronchitis and bronchiolitis as well as bloody fluid in the trachea and bronchi, 
hyperemic mucosa, submucosal hyperemia, focal hemorrhage, edema, and cellular 
infiltrate as well as loss of normal ciliated epithelia cells (Rothberg, Haessler, & 
Brown, 2008). In addition, varying numbers neutrophils and mononuclear cells mixed 
with fibrin and edema fluid present in the alveolar spaces and the alveolar capillaries 
are often remarkable hyperemic with intra-alveolar ducts and alveoli (Little, Hall, 
Douglas, Hyde, & Speers, 1976).  
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2.2.2 Influenza virus infection cycle 
The infection cycle of influenza A virus starts with the attachment of the virus to 
sialic acid residues present at the non-reducing termini of oligosaccharide chains of 
N-linked glycoprotein receptors on the host cell surface. The attached virus is 
internalized through endocytosis, followed by membrane fusion and uncoating of the 
virus envelope. Following entry into the host cell, the viral RNA is transported to the 
nucleus to undergo replication and transcription. Newly synthesized proteins and viral 
RNA are eventually transported to the host cell surface membrane to form new 
virions.  In this last stage of the virus infection cycle, the new infectious virions bud 
out of the host cell membrane with HA and NA present on the newly formed virus 
envelope that is derived from the host cell surface membrane (Viswanathan et al., 
2010).  
2.2.3 Glycoconjugates of the host cell surface 
Glycoconjugates represent a major network of informational molecules on the cell 
surface and extracellular matrix (ECM) of epithelial cells (Frevert & Sannes, 2005). 
Glycans on the cell surface are covalently attached to proteins or lipids to form 
glycoconjugates, which can be linear or branched in structure and participate in a 
number of diverse and complex cellular processes involved in regulating how the cell 
recognizes and interacts with its microenvironment. Glycoconjugates represent a vast 
repertoire of dynamic molecular antenna. These antenna, composed primarily of 
extended chains of complex carbohydrate (oligosaccharide) moieties are used by the 
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cell to initially regulate cell-cell and cell-ECM adhesion and resultant signal 
transduction pathways involved in such complex and diverse processes as 
embryogenesis, cancer metastasis, and response to infectious disease pathogens 
(Frevert & Sannes, 2005). Numerous studies have shown glycoconjugate 
oligosaccharides play an important role in microbial pathogenesis and invasion. Many 
microbial pathogens exploit host cell surface glycans as attachment sites or receptors 
that increase their ability to infect and invade host epithelia (Bernfield et al., 1999). 
The binding of pathogens to glycan receptors on host cells (microbial adhesion) is 
accomplished by microbial surface proteins recognizing specific host cell 
carbohydrate sequences or conformational domains. Accordingly, there is 
considerable interest in defining the oligosaccharide epitopes responsible for the 
microbial adhesion of numerous microbial pathogens in an effort to develop 
therapeutic receptor mimetics for the non-antibiotic prophylaxis or treatment of 
infectious disease.  Proof of concept for this approach has been provided by a recent 
study by Bergner et al (Bergner, Kuhlenschmidt, Hanafin, Firkins, & Kuhlenschmidt, 
2011). 
2.2.4 Human glycan receptors for influenza virus infection 
The human upper respiratory tract is the primary site of influenza A virus binding and 
the glycans terminated with sialic acid (SA) on the epithelial cell surface are receptors 
for this virus (Ge & Wang, 2011).  Attachment of influenza A virus to host cells is 
initiated through a binding domain on the HA which recognizes SA containing 
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glycans on the surface of epithelial cell (Y. Suzuki, 2005). The amino acid residues 
that form the binding domain are determinants for receptor specificity of H1, H2 and 
H3 viruses. The SAs are normally classified into 2 major groups, N-acetylneuraminic 
acid (NeuAc) or N-glycolylneuraminic acid (NeuGc), based on the modification of the 
C-5 amino group (T. Suzuki et al., 1997). The terminal sialic acids of glycans on cell 
surfaces are linked to galactose by either an α2,3 linkage (α2,3Gal) or an α2,6 linkage 
(α2,6Gal) and the distribution of these linkages as well as the specific types of SA (N-
acetyl or N-glycolyl) expressed on cell surfaces varies according to animal species. 
For example, bovine, equine and swine tissues possess both NeuAc and NeuGc, 
whereas human tissues possess only slight concentrations of NeuGc (less than 0.1% 
of total SA) (Y. Suzuki et al., 2000). Influenza A viruses also differ in their 
recognition of NeuAc, NeuGc (Higa, Rogers, & Paulson, 1985).  Most influenza A 
viruses isolated from avian preferentially recognize NeuAcα2,3Gal, whereas most 
human isolates preferentially recognize NeuAcα2,6Gal (Rogers & Paulson, 1983). 
This distinct receptor preference is due to specific amino acid differences in HA. For 
H1 viruses, avian virus isolates have a glutamate at position 190 (Glu-190) in the HA, 
but for human isolates position 190 is an aspartate (Asp-190) residue. Thus, Glu or 
Asp located at position 190 in the HA of influenza viruses determines preferential 
binding to α2,3 or α2,6 linkages, respectively (Kobasa et al., 2004; Matrosovich et al., 
2000; Stevens et al., 2004). In avian viruses, Gln at position 226 in HA (Gln-226) 
correlates with preferential binding to SAα2, 3Gal, whereas Leu-226 in human H2 
and H3 viruses determines HA specificity for SAα2,6Gal (Rogers & Paulson, 1983; 
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Matrosovich et al., 2000). In most human isolates, Leu-226 is accompanied with Ser-
228, whereas Gln-226 is accompanied with Gly-228 in avian viruses. NeuGcα2, 3Gal 
recognition has been found to be critical for viral infection and replication in ducks (T. 
Ito & Kawaoka, 2000) and horses (Y. Suzuki et al., 2000). Interestingly, swine 
influenza viruses bind equally well to both NeuAcα2,6Gal and NeuAcα2, 3Gal (T. Ito 
et al., 1997; T. Suzuki et al., 1997). In addition, in the human respiratory tract the 
predominant receptors on epithelial cells are SAα2,6Gal-terminated glycans, whereas 
SAα2,3Gal-terminated glycans predominate on intestinal epithelial cells of ducks (T. 
Ito et al., 1997; Y. Suzuki, 2005). Combined with the virus binding preferences 
described above, a hypothesis has been proposed: the type of linkage of SA molecules 
to galactose on the host cell surface is responsible for the host range restrictions of 
influenza viruses. However, both human (α2,6) and avian (α2,3) receptors have been 
found in pig trachea (T. Ito et al., 1998;Y. Suzuki et al., 2000), in the intestine and 
trachea of quail (Wan & Perez, 2006) and the respiratory tract of humans (Shinya et 
al., 2006). These relatively recent findings suggest the host restriction of influenza A 
viruses is dynamic and dependent on host exposure. 
2.2.5 Mixing vessel hypothesis 
In 1985, Scholtissek et al., who proved that swine infected with swine influenza virus 
also could be dually infected with human or avian influenza A virus, proposed the 
―mixing vessel‖ hypothesis (Scholtissek, Bürger, Kistner, & Shortridge, 1985). Such a 
dual infection may produce viral reassortants containing swine, human, and/or avian 
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genes by antigenic shift. Sometimes, this combination of swine, human and avian 
genes may produce a human pandemic virus by introduce unique virus serotypes into 
the human population. The ―mixing vessel hypothesis‖ was formulated based on the 
genetic similarities between certain subtypes of swine, human and avian influenza 
viruses and the susceptibility of swine to infection by both avian and human viruses 
(Ma et al., 2009).  
 
In support of this hypothesis is the receptor specificity of avian and human influenza 
viruses. As stated above, avian viruses preferentially bind to SAα2,3Gal-terminated 
oligosaccharides while human viruses incline to bind SAα2,6Gal-terminated 
oligosaccharides, and these receptor types are differentially expressed in avian and 
human epithelial cell surfaces. In contrast, both receptor types can be expressed on the 
respiratory tract of swine (T. Ito et al., 1998). So Swine are susceptible to both human 
and avian viruses. Thus, virus binding to specific terminal sialic acid linkages on host 
cell surface glycoconjugates is not only a required step for virus infectivity, but also 
for controlling tissue tropism and host range. Therefore, blocking virus binding by 
using exogenously added, for example in human infant formula, natural 
oligosaccharides as receptor competitors may be an attractive approach for developing 
antiviral nutriceuticals. Such nutriceuticals may prove extremely useful in situations 
of vaccine failure or vaccine unavailability. 
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2.3 Respiratory syncytial virus 
2.3.1 Introduction 
Respiratory syncytial virus (RSV), first characterized in 1957, has long been 
considered as the most important cause of acute lower respiratory tract infection in 
infants and young children worldwide (C. Hall, 1999). RSV is highly contagious, 
approximately 70% of young children will acquire RSV infection during the first year 
of life (B. S. Graham, Johnson, & Peebles, 2000). When children are infected with 
RSV, most of them suffer from mild upper respiratory tract infection, but 
approximately 40% of these infections will develop lower respiratory infections (D. K. 
Shay, Holman, Newman, Liu, Stout, & Anderson, 1999). In immune compromised 
patients, RSV infection can cause respiratory failure resulting in a high (up to 70%) 
mortality rates (Hertz, Englund, Snover, Bitterman, & McGlave, 1989). Unfortunately, 
there is no effective RSV vaccine available. 
2.3.2 Virology 
RSV is a member of Paramyxoviridae family of ribonucleic acid viruses.  RSV was 
first isolated in 1956 from a colony of chimpanzees with coryza and designated 
chimpanzee coryza agent. Shortly thereafter it was identified from an infant with 
bronchitis. Negative staining electron microscopy reveals RSV virions are 
pleomorphic and have a nucleocapsid enclosed by lipid envelopes with a diameter 
ranging from 150-300 mm (Chanock, R.M 1957). The RSV genome is a single-
stranded negative-sense RNA and encodes 11 proteins: non-structural (NS2, NS1), 
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nucleocapsid (N),phosphoprotein (P), matrix (M1), small envelope (M2), small 
hydrophobic (SH), RNA-dependent RNA polymerase (L), surface fusion glycoprotein 
(F) and surface attachment glycoprotein (G) (Hacking & Hull, 2002). The lipid 
envelope surrounding the nucleocapsid is host-derived as a result of budding from the 
host cell surface, and contains three transmembrane glycoproteins encoded by virus: F, 
G, and SH. The NS1 and NS2 nonstructural proteins appear to preferentially inhibit 
IFN-α/β signaling by down regulation of Stat2 transcription activator expression (Lo, 
Brazas, & Holtzman, 2005). The G glycoprotein functions in attachment of RSV to 
the surface of host respiratory epithelial cells and variation in its carbohydrate epitope 
defines the antigenic determinant of the A and B subgroups of RSV (Peret, Hall, 
Schnabel, Golub, & Anderson, 1998). Both subgroups often circulate simultaneously 
within geographically confined epidemics, although group A is dominant (Falsey & 
Walsh, 2000). Currently, the relationship between RSV strain variation and 
pathogenesis is not well understood. Some results indicate more severe disease is seen 
in children with group A viruses infections (Falsey & Walsh, 2000), whereas many 
other studies suggest there is no differences in clinical severity between virus 
subgroups (Brandenburg, van Beek, Moll, Osterhaus, & Claas, 2000; Falsey & Walsh, 
2000). 
2.3.3 RSV infection 
RSV exposure by direct aerosol contact with the nose or eyes leads to viral infection 
in the nasopharynx within 4 to 5 days post-exposure and occasional spread to the 
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lower respiratory tract (C. B. Hall, 2001). Clinical signs of upper respiratory tract 
infection are common and include rhinorrhea, cough, and low-grade fever, whereas 
lower respiratory tract infections usually present as bronchiolitis and associated 
wheezing, air trapping, and increased airway resistance (Collins & Graham, 
2008).Pneumonia also is a frequent complication seen in RSV-infected infants (C. B. 
Hall, 2001; McNamara & Smyth, 2002). Infection of the upper respiratory tract 
usually is limited to the most superficial cells of the respiratory epithelium (J. E. 
Johnson, Gonzales, Olson, Wright, & Graham, 2006). In the lower respiratory tract, 
the major targets of RSV are the ciliated cells of small bronchioles and type 1 
pneumocytes located in the alveoli. Other cells, including non-ciliated epithelium and 
intra-epithelial dendritic cells (DCs) may also be infected, but basal cells are usually 
spared (J. E. Johnson et al., 2006).  
 
The cellular receptor for RSV has not been unequivocally identified, but in vitro 
studies provide some clues about the mechanisms of RSV entry. Heparin-like 
glycosaminoglycans, unbranched polysaccharide chains on the surface of most 
mammalian cells have been shown as receptors or co-receptors for RSV (Martínez & 
Melero, 2000) or are involved with virus entry (Hallak, Collins, Knudson, & Peeples, 
2000). Although glycosaminoglycans are believed to be important for RSV G protein 
interaction with target cells, the precise cellular receptor of RSV is still unknown. The 
RSV F protein, which mediates viral penetration by fusion of the viral envelope with 
the host cell plasma membrane, has been shown to bind to intercellular adhesion 
22 
molecule-1 (ICAM-1) (Behera et al., 2001; Kurt-Jones et al., 2000; Malhotra et al., 
2003). In addition, electron microscopy studies have shown the virus G protein, and 
the host-cell-derived lipid, GM1, are mainly distributed in virus filaments (Jeffree et 
al., 2007). Further, lipid raft domains have been implicated in the assembly of new 
virus particles (Brown et al., 2004; Jeffree, Rixon, Brown, Aitken, & Sugrue, 2003). 
2.3.4 Pathogenesis of RSV disease 
The mechanism(s) of RSV pathogenesis is not well understood. The relative 
contribution of viral versus various host factors remains controversial (DeVincenzo, 
2005; Groothuis, Hoopes, & Jessie, 2011). RSV pathogenesis is affected by a number 
of host factors, such as the age of infection, genetic predisposition, and host immune 
response (DeVincenzo, 2005). Additionally, the state of immune maturation early in 
life is also an important determinant for RSV infection. RSV-specific maternal serum 
antibodies have been shown to suppress antibody and T-cell responses to primary 
RSV infection (DeVincenzo, 2005). 
 
While details of molecular mechanisms underlying RSV disease are not well 
understood, abundant evidence indicates the early inmate host response to primary 
infection is important. Overly robust inflammatory responses strongly correlated with 
the severity of RSV disease. For example, several studies have demonstrated that 
RSV could exacerbate asthma and bronchiolitis (Sikkel, Quint, Mallia, Wedzicha, & 
Johnston, 2008), and that these conditions are accompanied by inappropriate cytokine 
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expression, enhanced CD4 T-cell responses, inflammation and reduced immune 
regulation (Kallal & Lukacs, 2008; Sikkel et al., 2008). A large variety of 
inflammatory mediators are produced in the response to RSV infection, and there is 
controversy as to their relative importance (Oshansky, Zhang, Moore, & Tripp, 2009): 
Th2-type biased immune response caused by some RSV antigens have been supported 
by considerable evidence (Becker, 2006b; B. S. Graham, Johnson, & Peebles, 2000a; 
MARTINEZ, 2003; van Schaik, Welliver, & Kimpen, 2000), but other studies have 
indicated Th1-biased response or mixed responses associated with severe pediatric 
RSV infection (Brandenburg et al., 2000; Castro et al., 2008; Garofalo et al., 2001). 
 
The fact that RSV infects infants very early in life suggests that features modulating 
innate immunity play an important role in the disease process, and it is possible these 
features are related to RSV activation of pathogen recognition receptors (PRR) or toll-
like receptors (TLR) (Pasare & Medzhitov, 2004). How RSV recognition and the 
subsequent immune responses are regulated by the individual PRRs or TLRs remains 
unclear. Some studies suggest surface and cytoplasmic TLR including TLR2, TLR3, 
TLR4 and RIG-I may recognize RSV (Groskreutz et al., 2006; Groskreutz et al., 2006; 
Haynes et al., 2001; Murawski et al., 2009). Studies show that RSV can modify the 
expression patterns of cytokine and chemokine expression during infection 
(Groskreutz et al., 2006; B. S. Graham, Johnson, & Peebles, 2000), and may result in 
immune deregulation.  
The quality of adaptive immunity to RSV infection is significantly influenced by the 
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interface with the innate immune response. Inappropriate innate and inflammatory 
responses caused by RSV disease may lead to inappropriate T-cell responses. There 
are considerable evidences of a Th2-type biased immune response specific for some 
RSV antigens (Becker, 2006a; B. S. Graham, Johnson, & Peebles, 2000d). 
In summary, there is no single or typical pattern for how the cascade of inflammatory 
mediators affects RSV disease pathogenesis. RSV pathogenesis is the result of 
multiple factors including virus replication, and aberrant innate and adaptive immune 
responses.  
 
RSV disease in children 
RSV has been primarily known as young children’s virus. RSV is associated 
with50%-90% of cases of bronchiolitis and 5%-40% of cases of pneumonia in young 
children (Miller, 2010). The incidence of RSV in children is significant. It is 
estimated that 55,000 to 125,000 RSV associated pediatric hospitalizations and has a 
mortality rate of about 2% in the United States annually (Cooper, Banasiak, & Allen, 
2003; Susan, 2010; C. B. Hall et al., 2009; D. K. Shay, Holman, Roosevelt, Clarke, & 
Anderson, 2001).  Some studies suggested that there is an association between early, 
severe RSV infection, and recurrent wheezing or asthma in later childhood (Langley 
& Anderson, 2011; Sigurs et al., 2005). However, whether RSV infection sets up a 
process that leads to recurrent wheezing or, alternatively, severe disease in children 
already predisposed to recurrent wheezing has yet to be determined (Korppi, Piippo-
Savolainen, Korhonen, & Remes, 2004; Sigurs et al., 2005). 
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2.4 Human milk oligosaccharides and lipids as inhibitors 
2.4.1 Introduction 
Breastfeeding is considered to be one of the most cost-effective community health 
practices for the prevention of infant morbidity and mortality caused by infectious 
disease (Black, Morris, & Bryce, 2003). Additionally, human milk is not only widely 
recognized as the ideal food for young infants, it also is considered the model 
―nutriceutical‖, or food contributing nutritional or health benefits (Morrow, Ruiz-
Palacios, Jiang, & Newburg, 2005). Human milk has been reported to provide 
protection from respiratory tract infections, diarrheal diseases, bacteremia and 
meningitis (Hamosh, 2001; Morrow & Rangel, 2004). This protection afforded to 
breastfed infants is thought to be due to a variety of complementary components, such 
as colostrum antibodies, and probiotics, found in human milk. Besides milk antibodies, 
there are many non-immunological factors in human milk, which are considered to 
have antimicrobial activity, including oligosaccharides and lipids (Espinosa et al., 
2007; C. E. Isaacs, Thormar, & Pessolano, 1986). 
2.4.2 Structure of human milk oligosaccharides 
Among the forms of carbohydrate in human milk, such as lactose, glycolipids, 
glycoproteins, mucins, glycosaminoglycans, and oligosaccharides, the 
oligosaccharides are present in the greatest abundance. One liter of human milk 
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includes approximately 5-10 g of unbound oligosaccharides, which comprises the 
third largest solid component in milk, after lactose and triglyceride (Bode, 2009). 
Human milk oligosaccharides (HMO) consist of combinations of five different 
monosaccharides: D-glucose (Glc3), D-galactose (Gal), N-acetyl-glucosamine 
(GlcNac), L-Fucose (Fuc), and sialic acid (NeuAc) (McVeagh & Miller, 1997). In 
most milk oligosaccharides, lactose (Galβ1-4Glc) forms the reducing end, and fucose 
and/or sialic acid forms the non-reducing terminus. Lactose can be sialylated in α2,3 
and/or α2,6 linkages to form 3′sialyllactose and 6′sialyllactose, respectively (C. Kunz, 
Rudloff, Baier, Klein, & Strobel, 2000). In addition, lactose can also be fucosylated in 
α1,2 and α1,3 linkages to form 2′-fucosyllactose and 3-fucosyllactose, respectively 
(McVeagh & Miller, 1997; Newburg, 1996). These trisaccharides are recognized as 
the short-chain milk oligosaccharides. More complex milk oligosaccharides are 
formed through the elongation of lactose with up to 15 N-acetyl lactosamine repeats 
units (Galβ1-3/4GlcNAc). In the complex oligosaccharides, lactose or the 
polylactosamine backbone can be fucosylated in α1,2, α1,3, and/or α1,4 linkages 
and/or sialylated in α2,3 and/or α2,6 linkages. At present, approximately 200 different 
complex oligosaccharides have been identified in pooled human milk (Ninonuevo et 
al., 2006). 
2.4.3 Oligosaccharides as soluble receptor decoys for pathogenic bacteria and 
viruses 
For many years, milk oligosaccharides were thought to only contribute to the 
development of a specific intestinal flora in infants. Today, there is increasing 
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evidence that oligosaccharides in human milk may also function as soluble receptor 
analogues or decoys of epithelia cell-surface carbohydrate receptors (C. Kunz, 
Rudloff, Baier, Klein, & Strobel, 2000). Because milk oligosaccharides survive 
gastric acid hydrolysis and digestion/fermentation in the small intestine, their 
antimicrobial activity mostly depends on their structural configuration (Espinosa et al., 
2007). Thus, their specificity and affinity for competing with epithelial cells to 
impeding pathogens are determined by their structure (Sharon & Ofek, 2000).  
 
Pathogen adhesion to the epithelial cell is the prerequisite step for infection. Microbial 
binding proteins, such as bacterial adhesins, and virus hemagglutinins, recognize 
carbohydrate termini on host cell surface glycoconjugates. As discussed earlier for 
influenza, these receptors also determine the tissue tropism and host range of an 
invading pathogen (Schneider-Schaulies, 2000). Similarly, humans of a given blood 
group type are more susceptible to certain pathogens because of the presence of 
particular carbohydrate receptors on their epithelial cell membranes (McVeagh & 
Miller, 1997). Although many of these carbohydrate receptors exhibit remarkable 
structural specificity (e.g., α2,6vs.α2,3 sialic acid binding by influenza viruses (Zopf 
& Roth, 1996)), their binding affinity, especially when added as soluble 
oligosaccharides is likely too weak to effectively compete for pathogen binding unless 
they are present in high concentrations similar to that found in human milk or as 
multivalent aggregates (Bergner, Kuhlenschmidt, Hanafin, Firkins, & Kuhlenschmidt, 
2011), such as exists on the milk fat globule membrane (Sánchez-Juanes, Alonso, 
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Zancada, & Hueso, 2009). Pathogen-binding carbohydrate receptors present on host 
cell plasma membrane are in the form of multivalent glycoprotein or glycolipid 
aggregates or domains. Such a configuration greatly increases the binding avidity 
between pathogen and host cell and thus is frequently resistant to competition by 
soluble oligosaccharides added in relatively low (<1 mg/ml) concentration (Bergner, 
Kuhlenschmidt, Hanafin, Firkins, & Kuhlenschmidt, 2011a; M. D. Rolsma, 
Kuhlenschmidt, Gelberg, & Kuhlenschmidt, 1998).  
 
Currently, there are at least 20 specific human milk oligosaccharides known that could 
competitively bind to pathogens of the intestinal, respiratory and urinary tract and the 
number is growing rapidly (Bode, 2009). These pathogens not only include bacteria, 
viruses but even yeast (Candida albicans) (McVeagh & Miller, 1997). For example, 
the attachment of influenza virus could potentially be blocked by either 
NeuAc(α2,6)Lac (influenza virus A), NeuAc(α2,3)Lac (influenza virus B) in human 
milk (W. Weis et al., 1988). Milk oligosaccharides also prevent the adhesion of 
Streptococcus pneumoniae and Haemophilus influenzae to pharyngeal or 
buccalepithelial cells (Rudloff, Pohlentz, Diekmann, Egge, & Kunz, 1996). Sialylated 
HMO also block the binding of Escherichia coli strains that cause neonatal meningitis 
and sepsis (C. Kunz & Rudloff, 1993). Compared to formula fed infants, these 
pathogens are found less commonly in the stool of breast fed infants (C. Kunz & 
Rudloff, 1993). Furthermore, Human milk oligosaccharides also prevent 
haemagglutination of E. coli and Vibrio cholera (Newburg, 1996). Hence, human milk 
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bathes the epithelial cell membrane of the nasopharyngeal, gastrointestinal and 
urinary tracts of infants with oligosaccharides that may represent an important 
antimicrobial component that reduces the incidence of infectious disease in the breast 
fed infant.  
2.4.4 Summary 
Adhesion to host cells is a prerequisite for the infection of microbial pathogens. 
Human milk oligosaccharides competitively bind to the pathogen’s carbohydrate-
binding proteins and thereby facilitate pathogen clearance by the physiology 
mechanism characteristic of the host tissue, such as mucociliary action in the 
respiratory tract or bulk fluid movement in the gastrointestinal tract (Ebrahim, 1997). 
Now that the efficient, large-scale synthesis of some human milk oligosaccharides is 
possible, it may also be feasible to add bioactive HMO to infant formula to enhance 
its antimicrobial activity similar to that seen for human breast milk. Since HMO are 
natural products, they represent effective, safe, non-immunogenic and non-drug 
alternatives to, or supplements for, antibiotics or vaccines. Furthermore, because 
oligosaccharides do not act by killing or arresting the growth of the pathogens, 
resistance to them is less likely to develop. 
2.5 Antimicrobial lipids in human milk 
2.5.1 Introduction 
In addition to their nutritional value, human milk lipids have broad-spectrum 
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antimicrobial activity. The antimicrobial ability of lipids, in particular fatty acids, has 
been studied since the late nineteenth century (Kabara, Swieczkowski, Conley, & 
Truant, 1972a; Kabara, 1980). Lipid-dependent antimicrobial activity in milk is 
associated with the release of monoglycerides and free fatty acids by lipolysis from 
milk triglycerides. These triglycerides are present in the form of fat globules and 
contribute 98% of the milk fat (Jensen, 1996). Monoglycerides and diglycerides are 
present in trace amounts. The triglyceride core of the milk fat globule is covered by a 
membrane of polar lipids and forms an organized structure known as the milk fate 
globule membrane (MFGM).  The MFGM protects the triglycerides from hydrolysis 
by lipases in milk, and then the antimicrobial activity of these lipids is released by the 
combination of gastric lipases and pancreatic collapse in the infant’s gastrointestinal 
tract (C. E. Isaacs, Kashyap, Heird, & Thormar, 1990). Lipids are one of a number of 
non-speciﬁc and nonimmunologic protective factors existing in human milk which 
function at mucosal surfaces (Hosea Blewett, Cicalo, Holland, & Field, 2008). 
Nonspecific protective factors like lipids are thought to prevent or inhibit the 
establishment, multiplication and spread of invading pathogens in the host (C. E. 
Isaacs, 2011). 
2.5.2 Antimicrobial mechanism of milk lipids 
Human milk lipids can inactivate numerous enveloped viruses, including HSV (C. E. 
Isaacs, Thormar, & Pessolano, 1986), inﬂuenza virus (Kohn, Gitelman, & Inbar, 
1980), respiratory syncytial virus (Hilmarsson, Traustason, Kristmundsdóttir, & 
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Thormar, 2007), measles virus, VSV and visna virus (C. E. Isaacs, Thormar, 
&Pessolano, 1986), mouse mammary tumor virus (N. H. Sarkar, Charney, Dion, & 
Moore, 1973), dengue virus types 1 to 4 (Falkler, Diwan, & Halstead, 1975), 
Cytomegalovirus (Welsh, Arsenakis, Coelen, & May, 1979), SemlikiForestvirus 
(Chirico, Marzollo, Cortinovis, Fonte, & Gasparoni, 2008), Japanese Bencephalitis 
virus (Fieldsteel, 1974), HIV and simian immune deﬁciency virus (C. E. Isaacs, 
Thormar, & Pessolano, 1986c; Li et al., 2009). Human milk lipids also inactivate both 
Gram-positive (Staphylococcus epidermidis) and Gram-negative (Escherichia coli) 
bacteria (C. E. Isaacs, Kashyap, Heird, & Thormar, 1990), as well as the protozoal 
pathogens, such as Giardialamblia and Trichomonasvaginalis (Li et al., 2009; Rohrer, 
Winterhalter, Eckert, & Kohler, 1986) and Cryptosporidium parvum (Schmidt & 
Kuhlenschmidt, 2008). 
 
The antibacterial and antifungal ability of many of these bioactive lipids may be due 
to a membrane disruption mechanism as shown for enveloped viruses (Kabara, 
Swieczkowski, Conley, & Truant, 1972). Exposing bacterial to mild heating to 
increase membrane fluidity has been shown to increase lipid-dependent killing of the 
Gram-negative bacterial pathogens E. coli and Pseudomonas aeruginosaby 1,000 to 
100,000 fold, providing suggestive evidence that the bacterial membrane is the target 
of human milk (C. E. Isaacs, 2011). It should be noted, however, the normal mucosal 
barrier of the intestinal track might protect epithelial cells in the infant’s gut from 
damage following exposure to dietary fatty acids and monoglycerides (C. E. Isaacs, 
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2011). Although certain lipids are known to have detergent-like membrane 
solubilizing activity, there are other possible mechanisms, besides a direct effect on 
the cell membrane, which could explain their antimicrobial effects. For example, 
earlier studies have shown that unsaturated fatty acids affect cell signal transduction 
by inhibiting the influx of calcium through the plasma membrane of calcium depleted 
cells (Gamberucci, Fulceri, & Benedetti, 1997; Ordway, Singer, & Walsh Jr, 1991). 
Other studies indicate fatty acids inhibit the Fab I enzyme (enoyl-ACP reductase), 
which catalyzes the final reduction step of the fatty acid elongation cycle in P. 
falciparum (N.M., 2008; Tasdemir et al., 2007). 
2.5.3 Summary 
The research results summarized above suggest HML and perhaps HMO, especially if 
presented in the optimal spatial configuration, have potential as relatively inexpensive 
nutriceuticals to protect or treat infectious disease caused by a rather broad spectrum 
of microbial pathogens. Accordingly, the focus of the research described in this thesis 
is to begin to determine 1) which HML or HMO have the greatest antimicrobial 
effects, 2) their mechanism of action, and 3) whether they can be used singly or in 
combination as nutriceutical additions to infant formula to more closely simulate the 
antimicrobial effects of human breast milk. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Materials 
Unless stated otherwise, commercial lipids and oligosaccharides were obtained from 
Sigma Chemical Co. and V-Labs, respectively, and were of the highest purity 
available. Stock oligosaccharide concentrations were made to 100 mg/ml in sterile 
water and the diluted into the appropriate medium just prior to testing for inhibition of 
virus infectivity (see Virus Infectivity Inhibition Assay below).  Infant formulas (six 
proprietary formulations composed of different fat and protein system components 
(see Table 3.1) denoted as: XAD, XPE, XGE, XHE, XCE, XNE) were obtained in 
either liquid or powder form and stock concentrations of 0.5 -100 mg/ml (w/w) were 
prepared in sterile water.  These stocks were diluted in the appropriate medium just 
prior to testing for virus inhibition (see below).  Silica gel thin-layer chromatography 
(HPTLC or TLC) plates were obtained from Grace Alltech. Madin-Darby bovine 
kidney (MDCK) cells were used as the influenza virus (H1N1) host cell line and were 
obtained from the American Type Culture Collection (ATCC-CCL 22, Rockville, 
Maryland) and cultured in MEM supplemented with 10% fetal bovine serum (FBS) 
(Biowest, Miami, FL), and 2.0g sodium bicarbonate (Sigma, St. Louis, MO), and 
HEPES (Sigma, St. Louis, MO) at 37 C in 5% CO2.  Cell suspensions were obtained 
by harvesting flasks of confluent cells with 0.05% EDTA-trypsin (GIBCO, Carlsbad, 
CA). Influenza virus A/PR/8/34 (H1N1) were obtained from the American Type 
Culture Collection (ATCC) (VR 1469, Manassas, VA) and propagated on Madin 
Darby bovine kidney (MDCK) cells, and culture supernatants were harvested 24 to 72 
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h post infection (hpi) and stored at -80 C. Primary antibody against Influenza A 
nucleoprotein (NP) (cat. No. SC80481) and biotin conjugated secondary antibody 
goat anti-mouse IgG2a-B (cat. No. SC2073, were obtained from Santa Cruz 
Biotechnology, Santa Cruz, CA.  Peroxidase staining reagents were as follows: DAB 
reagent set kit (KPL, Gaithersburg, MD), goat serum (Vector, Burlingame, CA) and 
ABC kit (Vector, Burlingame, CA).  
3.2 Direct virus infectivity inhibition assay 
Measurement of the ability of potential inhibitors to directly block virus infection of 
host cells by inhibiting virus binding was performed as follows. Suspensions of 
MDCK cells were distributed to each well of 24-well plates (BD, Franklin Lakes, NJ) 
and incubated in a CO2 incubator at 37 C to establish monolayers. On the following 
day, potential inhibitors were serially diluted in MEM without serum in microfuge 
tubes (Eppendorf, Hauppauge, NY) to obtain an inhibitor concentration range of 0.01 
– 250mg/ml. Each inhibitor concentration (150 µl) and control MEM medium 
samples (150 µl) were combined with an equal volume of H1N1virus (1400 FFU). 
The microfuge tubes containing the inhibitor-virus mixture were vortexed and 
incubated in CO2 incubator at 35 C for 1 h. Following this pre-incubation MDCK cell 
monolayers in each well of a 24-well tissue culture plate were inoculated with 200 µl 
of either the pre-incubated control media or inhibitor-H1N1 mixtures for 30 min at 35 
C, in 5% CO2, to allow the virus to adsorb to the cell monolayers. At the end of this 
incubation the monolayers were washed and incubated in 1.0 ml MEM containing 5% 
tragacanth gum (Sigma, St. Louis, MO) and 2% FBS at 35 C for 24h. Tragacanth gum 
35 
was added to help produce homogeneously sized, easily countable foci in the FFU 
assay (see Measurement of virus infectivity: focus-forming assay, below) using 
modifications of a previously described procedure (Dobos, 1976). After several pre-
experiments (data not shown), a concentration of 5% tragacanth gum is found to be 
optimal for producing consistently sized, easily counted foci. 
3.3 Indirect virus infectivity inhibition assay 
The direct virus infectivity inhibition assay described above was used to screen the 
ability of putative virus inhibitors to block virus binding to host cells. To determine if 
any of the inhibitors testing positive in this screening assay could also block virus 
infectivity at stages in the virus-host cell infectious cycle other than initial virus 
binding, we developed an indirect virus infectivity inhibition assay. For this assay, 
potential inhibitors were added before, during, or after virus adsorption, in eight 
different combinations as shown in the Table 3.2. 
 
Monolayers of MDCK cells in 24-well plates were prepared as described above. Each 
well of 24-well plates were rinsed twice with 1 ml of PBS, and then varying amounts 
(0.01 – 250 mg) of inhibitors were diluted in 1.0 ml final volume of MEM plus 2% 
FBS  (MEM plus 2% FBS alone was used as the control) and the plates incubated at 
37 C for 5 h.  After this incubation, the medium was removed and cell monolayers 
rinsed twice with PBS. The monolayers were then inoculated with virus alone (1400 
FFU) or with virus plus inhibitor (inhibitor-virus mixtures in MEM plus 2% FBS as 
described above and incubated in a CO2 incubator at 35 C for 30 min). After virus 
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adsorption, monolayers were again washed twice in PBS and incubated in MEM-
2%FBS containing 5% tragacanth gum with or without inhibitors at 35 C for 24 h as 
previously described. 
3.4 Measurement of virus infectivity: focus-forming assay 
The following steps were carried out at room temperature (RT) on a rocker plate 
unless otherwise noted. The wells were rinsed twice with 1 ml of PBS. The monolayer 
in each well was fixed for 2 min with 500 µl of 95%ethanol: 10% buffered formalin 
(1:1). The monolayers were rinsed for 5min with 500 µl of 70% ethanol per well, 
followed by an additional 5 min rinse with 500 µl of 50% ethanol. The 50% ethanol 
was removed and replaced with150µl of on 3% H2O2 in wash buffer to quench 
endogenous peroxidase activity and processed for primary and secondary antibody 
staining to detect H1N1 infected cell foci as previously described (M. D. Rolsma, 
Kuhlenschmidt, Gelberg, & Kuhlenschmidt, 1998). Stained foci were observed and 
digital images automatically collected using a Nikon Eclipse TS100 inverted 
microscope (Nikon) equipped with a software (Metamorph)-controlled motorized 
stage (Optician, Prior Scientific).  
3.5 Organic solvent extraction of XPE 
XPE (0.75 g (wet weight=0.776 ml) was transferred to a glass tube and 2.0 ml of 
methanol followed by 1.0 ml of chloroform were added and mixed well by vortexing. 
After centrifugation of the extract at 1,000 g for 10 min (Sorvall Superspeed RC2-B, 
GSA rotor; Kendro laboratory Products, Newtown, Connecticut) the clear, single 
phase supernatant was transferred into a new glass tube and the pellet re-extracted 
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with 3 ml of chloroform-methanol-water 4:8:3. Following centrifugation this 
supernatant was mixed with the previous extract supernatant, evaporated to dryness 
and stored at 4 C until use.  All fractions generated during organic solvent 
fractionation were compared for antiviral activity based on the original XPE 
concentration in mg/ml by defining an XPE equivalent concentration. For example, if 
0.75 g in of XPE in 1 ml water was used as the starting concentration and the 
extraction process generated an aqueous and an organic fraction, each of which was 
evaporated and resuspended in water to 1 ml, then both the aqueous and organic 
extracts would contain 750 mg/ml equivalents of the original XPE. 
3.6 Thin-layer Chromatography 
Samples were dissolved in chloroform-methanol (9:1) and appropriate volumes 
(generally 5 to 20 µl) were applied in 0.5-cm steaks (separated by 0.5-cm blank lanes) 
on TLC plates (5 x 20 cm). The plates were developed in the chloroform-methanol 
(9:1) in a short-bed continuous-development chamber. Lipid bands were visualized by 
primulin spray (Sigma Chemical Co.). Semi-preparative TLC was performed under 
the same conditions except that analytes (200-300 µl) were streaked across the entire 
width of multiple silica gel TLC plates (Merck) using a manual TLC Streaker 
(Alltech). After development, the outer vertical edges of the plates were stained with 
primulin. These lanes were used as guide for dividing the unstained lanes into 
horizontal bands that extended across the entire width of the plate. The unstained 
middle portion of the lipid bands was scraped from the plates and exhaustively 
extracted with chloroform-methanol (9:1). Silica fines were removed by 
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centrifugation and filtration. Following evaporation and re-suspension in a volume of 
solvent equivalent to the original applied volume, appropriate aliquots were tested for 
inhibitory activity in the virus infectivity inhibition assays. 
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3.7 Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Infant formulations composed of different fat and protein system 
components. Infant formulas were obtained in either liquid or powder form and stock 
concentrations of 100 mg/ml (w/w) were prepared. NFMD: non-fat milk dehydrate; 
MG: milk fat globulin. 
 
 
 
Table 3.2. Description of the treatment conditions used in the indirect virus 
infectivity inhibition assay. Inhibitors were added before, during, or after virus 
addition to MDCK cells, in eight different combinations. Y: inhibitor added; N: no 
inhibitor added. 
  
Sample 
Protein system 
(per 100ml) 
Fat system (per 100ml) 
XGE 
1.5g hydrolyzed  
whey protein 
3.61g triglycerides. Oil 
blend 
XPE 
1.5g hydrolyzed  
whey protein 
2.17g triglycerides +1.84g 
predigested fat 
XNE 
4.3g Intact 
caseinprotein 
None 
XHE 
4.3g 
hydrolyzedcasein 
protein 
None 
XCE 
1.41g protein from 
NFMD+whey 
protein concentrate 
2.14g triglycerides +1.5g 
predigested fat(oil blend) 
XAD 
1.41g protein from 
condensed 
milk+whey protein 
concentrate 
3.64g fat(include MG and 
lecithin) 
Column No 1 2 3 4 5 6 7 8 
Pretreat MDCK cell 5 h Y Y N Y Y N N N 
Inhibitor in adsorption Y N Y Y N N Y N 
Inhibitor in medium 24h Y Y Y N N Y N N 
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3.8  Statistical analysis 
All statistical analyses were carried out using Statistical Package for the Social 
Sciences (SPSS) 16.0. Statistical probability of P < 0.05 was considered significant. 
Univariate analysis of variance was done to compare the effects of various 
concentrations of different inhibitors on H1N1 infectivity. The effects of different 
treatment of inhibitors on H1N1 infectivity and virus attachment were analyzed using 
a one-way analysis of variance (one-way ANOVA) followed by Bonferroni’s post hoc 
test to determine differences between each treatment. 
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CHAPTER 4: RESULTS 
4.1 Validation of FFU assay: 
In order to validate the number of focus forming units detected in the focus forming 
assay was proportional to the concentration of H1N1 virus concentration used to 
infect MDCK host cells, cell monolayers were exposed to the different H1N1 
concentrations. Two-fold serial dilutions of virus stocks were added to MDCK cells 
for 30 min, the cell layers washed, and incubated at 35 C for 24 h as described in 
Materials and Methods. Infected cell foci (FFU) were visualized by DAB staining as 
previously described (M. D. Rolsma et al., 1998), using anti-H1N1 monoclonal 
antibody (antibody against Influenza A nucleoprotein (NP) from Santa Cruz 
Biotechnology, Santa Cruz, CA) to detect the presence of H1N1 viral progeny. 
Digital images (24/well of a 24-well plate) of infected cell monolayer were captured 
by automated microscopy and infected cell foci counted as previously described 
(Andres et al., 2007). As shown in Figure 4.1, a positive linear correlation was 
observed between the percentage of infected cells and the concentration of virus used 
to inoculate MDCK cell monolayers.  
4.2 Screening of selected HMO for inhibition of virus infectivity 
To examine whether human milk oligosaccharides could potentially serve as receptor 
decoys for H1N1 influenza virus, we selected commercially available 
oligosaccharides known to be present in relatively high concentration in human milk 
(C. Kunz, Rudloff, Baier, Klein, & Strobel, 2000), including those with non-reducing 
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terminal sialic acid, a sugar epitope known to bind type A influenza viruses. The 
oligosaccharides (0.1 – 10 mg/ml) tested were lacto-N-neotetraose (LNnT), 3'-
sialyllactose (3-SL), 6'-sialyllactose (6-SL), 2'-Fucosyllactose (2-FL), Sialic acid (SA) 
and also the prebiotic Galacto-oligosaccharides (GOS), Fructo-oligosaccharides 
(FOS). Virus infectivity in the presence and absence of oligosaccharide (0.1 – 10 
mg/ml) was scored as the percent of control FFU values obtained in the presence of 
virus alone. The result of initial screening of HMO inhibitory activity is shown in 
Figure 4.2.  
None of the HMO tested were able to affect 50% inhibition of virus infectivity at 
concentrations equal to or less than 1 mg/ml.  Although, LNnT appeared to inhibit 
infectivity by 50% at 1 mg/ml the effect was not dose-dependent. In subsequent 
experiments using a larger concentration range, LNnt displayed an IC50 (concentration 
causing a 50% inhibition of virus infectivity) value ≥ 10 mg/ml. Similarly, none of the 
HMO tested were able to dose-dependently block 50% virus infectivity at 
concentrations below 10 mg/ml with the exception of 2-FL, 3-FL, 3-SL and SA. 
Compared to HMO, the prebiotics GOS and FOS displayed almost no ability to 
inhibit H1N1 (Fig. 4.3). A summary of the IC50 values for all putative oligosaccharide 
inhibitors is shown in Table 4.1. 
4.3 Screening of infant formula compounds and human milk for inhibition of 
virus infectivity 
Although the HMO displayed relatively weak antiviral inhibitory activity, it is 
possible that the addition of selected HMO to infant formula may enhance their 
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antiviral activity. one plausible mechanism by which this could potentially occur is 
via adsorption or incorporation of the HMO into fat globules or micelles of the oil 
components of infant formula. Such an HMO-lipid complex may present the 
oligosaccharide as a multivalent aggregate thereby increasing its aviditiy for virus 
sugar receptors. Accordingly, we screened as part of initial control experiments, a 
numer of different infant formulasand human milk for their ability to inhibit H1N1 
activity using the direct virus infectivity inhibition assay. Each compound was tested 
in duplicate using dilution series comprised of 10 different concentrations. 
Representative results of a subset (4 concentrations) of these dilution series are shown 
in Figure 4.4 (see Table 4.2 for a summary of the IC50 values determined by analysis 
of all inhibitor dilution series experiments). These results indicate certain infant 
formulas exhibited anti-influenza activity in a dose dependent manner at the indicated 
concentration range. Among these infant formulas, XPE possessed the greatest viral 
inhibitory activity (IC50 = 1 mg/ml, Table 4.2).  Except for XPE, and human milk, 
which have IC50 values of 0.98 mg/ml and 1.95 mg/ml respectively, none of the other 
infant formulas were able to does-dependently inhibit virus infectivity by 50% at 
concentrations below 2 mg/ml. The order of inhibitory potency was XPE> XCE> 
XGE. Formulas XNE, XHE, and XAD displayed no antiviral activity.  The finding 
that some infant formulas displayed relatively potent indigenous antiviral activity was 
somewhat unexpected. Thus, XPE was chosen for further exploration of the 
mechanism responsible for its ability to inhibit H1N1 infectivity. 
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The dose-response curves for XPE and human milk are shown in Figure 4.5. The 
lowest concentration of XPE causing detectable inhibition of virus infectivity was 
observed between 60 and 240µg/ml. This was similar to the minimal inhibitory 
concentration (120 – 480 µg/ml) required for human milk. Furthermore, the 
concentrations of XPE and human milk causing maximal inhibition of virus 
infectivity also were in the same range (4-16 mg/ml). Since XPE contains no HMO, 
these results suggest XPE and human milk may contain similar, non-HMO antiviral 
components.  
4.4 Initial characterization of the mechanism of action of XPE 
To begin to characterize the mechanism by which XPE inhibits virus infectivity, we 
first sought to determine if XPE acts on the virus or on the host cell. Thus, XPE was 
added before, during, and after the virus adsorption period and the effect on virus 
infectivity evaluated using the indirect virus infectivity inhibition assay as described 
in Materials and Methods. The results of these experiments demonstrated that when 
XPE is present in the cell culture medium, no matter if added before, during, or after 
virus adsorption, H1N1 infectivity was inhibited (Figure 4.6). The extent of this 
inhibition varied; however, depending on when XPE was added during the cell 
infection cycle. The greatest inhibition was seen when XPE was present at all three 
stages of the infectious cycle (adsorption, entry, and replication; Fig. 4.6, column 1). 
Under these conditions, virus infectivity was inhibited >98%. Most of this inhibition 
could be explained by XPE’s ability to block virus adsorption to host cells (Fig. 4.6, 
columns 1, 3, 4, 7), Interestingly, when XPE was only added to host cells prior to 
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virus inoculation and then removed, (Fig. 4.6, column 5) or after virus adsorption was 
complete (Fig. 4.6, column 6), virus infectivity could still be reduced by 20%, and 
60%, respectively. 
4.5 The inhibitory component in XPE is a lipid 
In an effort to identify the active component of XPE responsible for its rather 
profound virus inhibitory activity, we subjected XPE to biochemical fractionation. 
XPE is composed of protein system and fat system; however, XHE has the same 
protein system but no fat system (Table. 4.3). Comparison of the inhibitory activity 
between XPE and XHE is shown in Fig. 4.7. Relative to XPE, XHE had detectable 
virus inhibitory activity at relatively high concentrations (250 mg/ml), but not at 
lower concentrations (≤ 62.5 mg/ml). Based on this result, we hypothesize the fat 
system may contribute to the antiviral effect of XPE. To test this hypothesis, organic 
solvent of extraction of XPE was performed as described in the Material and Methods 
and both the organic and aqueous extracts were tested for antiviral activity (Fig. 4.8). 
 
Compared to the aqueous extract, the organic extract of XPE (Fig. 4.8) exhibited an 
extraordinary antiviral activity, which can still inhibit approximately 90% of virus 
infection at a concentration of 490µg/ml. Aqueous extract of XPE have almost no 
inhibitory effect except at high concentrations. This result supports our pervious 
hypothesis that the fat system of XPE contributes to the antiviral activity of XPE. 
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4.6 Purification of antiviral lipid from XPE organic extracts 
Individual lipids in XPE organic extracts were separated by analytical TLC and band 
visualized by primulin staining. Three distinct, primulin-staining bands (Mid1, Mid2, 
and sample origin), and a diffuse band containing multiple weakly stain bands (Top) 
were observed and labeled based on their relative chromatographic mobility (Fig. 4.9). 
A no-band zone (Bot), located between the sample origin and Mid1 bands also was 
identified so that all areas of the plate were represented during subsequent semi-
preparative TLC, and analysis for antiviral activity. Semi-preparative TLC, band 
harvesting and testing for antiviral activity were performed as described in Materials 
and Methods. Following semi-preparative TLC, aliquots of each of the harvested 
areas (defined above) of the plate were re-chromatographed on analytical TLC plates 
along with the non-fractionated XPE organic extract so that degree of purity of each 
of the identified XPE lipid bands could be verified (Fig. 4.9). Note the sample origin 
band was not visible following semi-preparative TLC and re-chromatography on 
analytical plates. This result suggests the original primulin staining band seen 
following initial analytical TLC was likely due to sample residue at the origin rather 
than a unique non-mobile lipid. The antiviral activity of each of the bands/areas 
recovered from the semi-preparative TLC plate is shown in Figure 4.10. Only fraction 
Mid2 displayed antiviral activity.  This fraction contained a single lipid band (Fig. 4.9) 
and was designated as lipid M2. 
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To further characterize the biological activity of lipid M2 and to determine whether it 
is responsible for the antiviral activity of XPE, we assessed whether its site of action 
was on H1N1 or host cells or both, as was the case for XPE using the indirect virus 
infectivity inhibition assay (Fig. 4.11). The antiviral activity of lipid M2 appeared 
identical to XPE including its ability to block virus infectivity following virus 
absorption and entry into the host cell. When lipid M2 is present in the cell culture 
medium, no matter if added before, during, or after virus adsorption, H1N1 infectivity 
was inhibited. As seen with XPE, the strongest inhibition was observed when lipid 
M2 was present at all three stages of the infectious cycle (Fig. 4.6, column 1). Thus, 
we conclude that lipid M2 fraction is primarily responsible for the antiviral activity of 
XPE. 
4.7 Initial characterization of the lipid M2 
In an effort to identity the chemical nature of lipid M2, we compared its 
chromatographic mobility on TLC to known commercial fatty acids (Fig. 4.12). 
Interestingly, while Lipid M1 appears to be oleic acid (optimal separation of each of 
the fatty acid standards was no achieved in this solvent system), lipid M2 did not co-
chromatograph with any of the commercial lipids used as standards. It appears to have 
more polar character than any of the commercial fatty acid standards. To further 
characterize lipid M2, we compared the TLC profile of organic solvent extracts of 
XPE and XGE infant formulas (Fig. 4.13).  Formulas XPE and XGE are composed of 
the same protein system, but different fat systems (Table 4.3). Compared to XPE, 
XGE lacks the predigested fat component. Considering the IC50 of XGE is 8-fold 
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lower than XPE (Table 4.2), the predigested fat maybe contributing the lipid 
component responsible the antiviral activity of XPE (i.e., lipid M2). As expected, 
XGE displayed no lipid bands on TLC plate while lipid M2 is clearly detected in XPE. 
These combined results indicate the inhibitory lipid M2 is a part of the predigested fat 
component of XPE and is thus likely a lipolysis-generated fatty acid. Characterization 
of purified lipid M2 by TLC using multiple solvent systems and additional fatty acid 
standards as well as by ESI Mass Spectrometry is ongoing.   
4.8 Identification of inhibitory components in Human milk 
Based on our results demonstrating the presence of antiviral lipids in some infant 
formula, we sought to determine if human milk also contained bioactive lipids that 
were at least partially responsible for its ability to inhibit H1N1 infectivity. Lipid 
extraction of human milk was performed as described in the Material and Methods 
and both the organic and aqueous extracts were tested for antiviral activity (Fig. 4.14). 
The organic solvent extract of human milk displayed potent, dose-dependent antiviral 
activity, as did whole human milk. The aqueous extract, however, contained little, if 
any virus inhibitory activity. Thus, lipids in human milk appear responsible for at least 
a major portion of its antiviral activity. These results, combined with the identification 
of the virus inhibitory lipid M2, strongly support the conclusion that certain lipids 
have antiviral activity including those contained in human milk and justify the need 
for further research aimed at understanding their mechanism of action and exploring 
their use as antimicrobial nutriceuticals.  
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4.9 Mechanism of H1N1 inhibition by lipid M2 
The results above (Figs. 4.6, 4.11) suggest XPE (lipid M2) inhibits virus infectivity by 
acting directly on the virus and perhaps on MDCK cells as well. Since relatively little 
(20%) inhibition of virus infectivity is seen when MDCK cells are exposed to lipid 
M2 (Fig. 4.11) or XPE (Fig. 4.6) prior to virus inoculation, it is likely that most of the 
virus inhibitory activity is due to a direct action of lipid M2 on H1N1 resulting in 
blocking virus binding to host cells. The 20% inhibition seen during preincubation of 
MDCK cells with XPE or lipid M2 also could be due to direct interaction of the virus 
with residual lipid remaining bound to the host cell. To further address whether the 
inhibitory activity of Lipid M2is solely due to inhibition of virus binding or whether it 
can also inhibit the subsequent stages of virus entry or replication, we used 
modifications of the indirect virus infectivity inhibition assay (see Materials and 
Methods). For these experiments, virus was first incubated with MDCK monolayers 
at 4 C for 30 min to allow virus attachment and then Lipid M2 was added during virus 
entry as the cells were warmed to 35 C or during the virus replication stage (24 h 
incubation, 35 C) as described in Fig. 4.15. 
 
When Lipid M2 is added during virus binding at 4 C, it blocks approximately 50% of 
subsequent virus infectivity (Fig. 4.15, column 1). If Lipid M2 is added following 
virus binding at 4 C and then the cells warmed to 35 C to allow virus entry, 
subsequent virus infectivity is inhibited by ~40% (Fig. 4.15, column 2), while the 
same Lipid M2 concentration (4 mg/ml) blocks>90% virus infectivity when added 
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during virus adsorption/entry at 35 C (Fig. 4.6, column 7). When Lipid M2 is added 
only during the final 24 h incubation at 35 C (virus replication stage) infectivity was 
inhibited by approximately 60% (Fig. 4.15, column 3, Fig. 4.6, column 6), the 
combined effects of Lipid M2 on both virus binding and entry (Fig. 4.15 columns 1 
and 2) result in essentially 100% inhibition of infectivity and agrees with the result 
obtained when XPE (Lipid M2) is present through all stages of the virus infectivity 
cycle (Fig. 4.6, column 1). These results suggest Lipid M2 may inhibit virus 
infectivity not only by acting directly on the virus but also by at least partially 
inhibiting virus entry and perhaps subsequent virus replication. The proposed effect 
on virus replication; however, also may be at least partially explained by re-exposure 
of the newly formed virions to XPE or Lipid M2 as they emerge from infected cells. 
4.10 Statistical analysis of the anti-viral effect of inhibitors 
Statistical analysis of the effect of different XPE treatment conditions of MDCK 
Cells on H1N1 infectivity.  One-way ANOVA was used to analyze the effect of 
different XPE treatment conditions of MDCK Cells on H1N1 infectivity. Viral 
infectivity means and standard deviations and 95% confidence interval for mean are 
shown in Table 4.4. The F values and significance levels resulting from these data 
appear in Table 4.5. The effect of different XPE treatment conditions of MDCK Cells 
on H1N1 infectivity is significantly different (F(7, 30)=71.61, P < 0.001, Table 4.5.).  
A more detailed analysis, using Bonferroni’s post hoc test, was conducted to test for 
differences between each treatment. Result of Bonferroni’s post hoc test is presented 
in Table 4.6. Compared to negative control (NNN), all treatment conditions 
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significantly inhibited H1N1 infectivity (P < 0.001, respectively, Table 4.6.), except 
for XPE added before virus adsorption (YNN, P=0.449, Table 4.6.) and XPE added 
after virus adsorption (NNY, P=1.000, Table 4.6.). Among these treatment conditions 
that can significantly inhibit H1N1 infectivity, there is no significant difference. 
 
Statistical analysis of the effect of various concentrations of XPE and XHE on 
H1N1 infectivity. The effect of various concentrations of XPE and XHE on H1N1 
infectivity was analyzed by univariate analysis of variance. Descriptive statistics are 
shown in Table 4.7. Statistical analysis of the effect of concentration on the antiviral 
effect of XPE and XHE is shown in Table 4.8. The antiviral activity caused by XPE 
and XHE are significantly different (F=494.568, P < 0.001, Table 4.8.). Concentration 
also significantly influences the anti-viral effect of XPE and XHE (F=48.653, P < 
0.001, Table 4.8.). Moreover, the extent of anti-viral effect of each inhibitor 
influenced by concentration is significantly different (F=25.057, P < 0.001, Table 4.8.). 
Compared to XHE, the antiviral effect of XPE is more significantly influenced by its 
concentration.   
 
Statistical analysis of the effect of purified lipid fractions of XPE on H1N1 
infectivity. The effect of purified lipid fractions of XPE on H1N1 infectivity was 
analyzed using a one-way ANOVA followed by a one-way ANOVA to determine 
differences on individual fractions. Viral infectivity means, standard deviations and 95% 
confidence interval for mean are shown in Table 4.9. The F values and significance 
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levels resulting from these data are shown in Table 4.10. The effect of purified lipid 
fractions of XPE on H1N1 infectivity is significantly different (F(4, 5)=301.911, P < 
0.001, Table 4.10.). In order to compare the anti-viral effect caused by each purified 
lipid fraction, the Bonferroni’s post hoc test was performed. Result of Bonferroni’s 
post hoc test is shown in Table 4.11. The anti-viral effect of Mid2 lipid fraction is 
significantly higher than any other lipid fractions (P < 0.001, Table 4.11.). 
Additionally, there is no significant difference among Top, Mid1, Bot and Loading 
fractions. 
 
Statistical analysis of the effect of lipid M2 treatment conditions of MDCK Cells 
on H1N1 infectivity. To check for the effect of lipid M2 treatment conditions of 
MDCK Cells on H1N1 infectivity, a one-way ANOVA was performed. The effect of 
each treatment condition was then compared to each other using Bonferroni’s post hoc 
test. Viral infectivity means and standard deviations and 95% confidence interval for 
mean are shown in Table 4.12.The F values and significance levels resulting from 
these data are shown in Table 4.13.There are significant differences in the anti-viral 
effect caused by lipid M2 different treatment conditions (F(7,32)=162.227, P < 0.001, 
Table 4.13.). Using Bonferroni’s post hoc test, the difference between each treatment 
condition with lipid M2 was analyzed. Compared to negative control (NNN), all the 
lipid M2 treatment conditions have significant anti-viral effect (P <0.05, Table 4.14.), 
except for the condition when lipid M2 is added only after virus adsorption (NNY, 
P=0.323, Table 4.14.). Among these effective conditions, the greatest anti-viral effect 
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was observed when lipid M2 present during the virus adsorption, no matter if added 
before, and after virus adsorption (YYY, YYN, NYY, NYN, P < 0.001, respectively 
Table 4.14.). And there is no significant difference between these four treatment 
conditions (P =1, respectively, Table 4.14.)  
 
Statistical analysis of the effect of Lipid M2 on H1N1 Binding to MDCK cells.  
The Effect of Lipid M2 on H1N1 Binding to MDCK cells was analyzed by one-way 
ANOVA. Descriptive statistics are shown in Table 4.15. The F values and significance 
levels are shown in Table 4.16. The effect of Lipid M2 on H1N1 Binding to MDCK 
cells is significantly different between treatment conditions (F(4, 19)=72.823, P < 
0.001, Table 4.16.). Bonferroni’s post hoc test was conducted to test for differences 
between anti-viral effects in each treatment conditions. Compared to negative control 
(NNN), all the treatment conditions have significant antiviral effect (P < 0.001, 
respectively, Table 4.17.). Among these treatment conditions, lipid M2 added during 
viral entry and replication (NYY) has the highest antiviral effect (P < 0.005, Table 
4.17).  
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4.11 Figures and Tables 
 
Figure 4.1. H1N1 infectivity of MDCK cells is proportional to virus 
concentration. Inoculation of MDCK monolayers with H1N1 virus, detection, and 
measurement of infected cell foci was performed as described in Materials and 
Methods. (A), phase contrast photomicrographs show distinct foci of infection that 
increase in number upon increasing concentration of inoculating virus (left to right, 4 
fold virus dilution series, with the lower right image representing the negative control 
(no virus)). (B), graph demonstrates linearity of observed FFU with relative virus 
concentration. The relative virus concentration varied from 16-397 FFU units.  
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Figure 4.2. Effect of various HMO on H1N1 virus infectivity. Virus infectivity was 
measured in the presence and absence of the indicated oligosaccharides as described 
in Materials and Methods. Each oligosaccharide was tested in duplicate at four 
concentrations, 0.01, 0.1, 1.0, and 10 mg/ml.  
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Figure 4.3. Effect of prebiotics Gos and Fos on H1N1 infectivity. Virus infectivity 
was measured in the presence and absence of the indicated concentrations of GOS and 
FOS prebiotic oligosaccharides as described in Materials and Methods. (), FOS; (), 
GOS. 
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Figure 4.4. Effect of various infant formulas and human milk on H1N1 virus 
infectivity. Virus infectivity was measured in the presence and absence of the 
indicated concentrations of various infant formula or human milk as described in 
Materials and Methods. Each compound was tested in duplicate at the indicated 
concentrations. (A), comparison of virus inhibitory activity of various proprietary 
infant formulas; (B), comparison of the virus inhibitory activity of XPE (the most 
inhibitory formula) and human milk. 
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Figure 4.5. Comparison of the effects of various concentrations of XPE and 
human milk on H1N1 infectivity. Virus infectivity was measured in the presence and 
absence of the indicated concentrations of XPE and human milk as described in 
Materials and Methods. Each of the concentrations of XPE and milk were tested in 
duplicate. 
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Column No 1 2 3 4 5 6 7 8 
Pretreat 5 h Y Y N Y Y N N N 
XPE in adsorption Y N Y Y N N Y N 
XPE in medium 24h Y Y Y N N Y N N 
 
Figure 4.6. Effect of different XPE treatment conditions of MDCK Cells on 
H1N1 infectivity. The effect of different XPE treatment conditions (as denoted in the 
table above) on virus infectivity of MDCK cells were measured using the indirect 
virus infectivity inhibitory assay as described in Materials and Methods. Pretreat 5h: 
MDCK cells were preincubated 5 h with XPE in MEM-serum, at 35 C; XPE in 
adsorption: XPE was added to H1N1, incubated for 30 min at 35 C and then added to 
MDCK cells as described in Materials and Methods; XPE in medium 24h: XPE was 
added after virus adsorption to MDCK cells during the final 24 h virus replication 
incubation as described in Materials and Methods. XPE was used at a concentration of 
15.64 mg/ml. 
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Figure 4.7. Effect of various concentrations of XPE and XHE on H1N1 infectivity. 
Virus infectivity was measured in the presence and absence of the indicated 
concentrations of XPE and XHE using the direct virus infectivity inhibition assay as 
described in Materials and Methods. Each compound concentration was tested in 
duplicate. 
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Figure 4.8. Effect of XPE fractions on H1N1 infectivity. Virus infectivity was 
measured using the direct virus infectivity inhibition assay in the presence and 
absence of the indicated concentrations of intact XPE and its aqueous or organic 
extract fractions. Organic solvent extraction of XPE (0.75 g/0.75 ml) and 
measurement of virus infectivity was done as described in Materials and Methods. 
The XPE organic and aqueous extracts were diluted to equal the original intact XPE 
concentration (XPE Equivalent) so as to directly compare the relative inhibitory 
activity of each fraction. Five replicates of each compound were tested. 
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Figure 4.9.  Purification of lipid fractions from XPE organic solvent extract. The 
organic extract of XPE was prepared and subjected to semi-preparative TLC as 
described in Materials and Methods. All lipid staining and blank areas were scraped 
from the semi-preparative TLC plate and aliquots re-chromatographed on analytical 
TLC plates (shown in the above chromatogram). Note: each area recovered from the 
semi-preparative TLC plate (as denoted on the right edge of the figure) contained 
purified lipid band that displayed chromatographic mobility identical to those seen in 
the original XPE organic extract. XPE: organic extract of XPE; top, mid1, mid2, bot, 
and sample loading lances correspond to the areas scraped from the semi-preparative 
TLC plate and re-chromatographed on the analytical TLC plate shown in this figure. 
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Figure 4.10. Effect of purified lipid fractions of XPE on H1N1 infectivity. Virus 
infectivity was measured in the presence and absence of purified lipid fractions of 
XPE (as shown in Figure 4.9. above) as described in Materials and Methods. Each 
compound was tested in five-replicates at the XPE equivalent concentration of 4 
mg/ml. 
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Column No 1 2 3 4 5 6 7 8 
Pretreat 5 h Y Y N Y Y N N N 
Lipid M2 in adsorption Y N Y Y N N Y N 
Lipid M2 in medium 24h Y Y Y N N Y N N 
 
Figure 4.11. Effect of lipid M2 treatment conditions of MDCK Cells on H1N1 
infectivity. The effect of different lipid M2 treatment conditions (as denoted in the 
table above) on virus infectivity of MDCK cells were measured using the indirect 
virus infectivity inhibitory assay as described in Materials and Methods. Pretreat 5h: 
MDCK cells were preincubated 5 h with lipid M2 in MEM-serum, at 35 C; Lipid M2 
in adsorption: Lipid M2 was added to H1N1, incubated for 30 min at 35 C and then 
added to MDCK cells as described in Materials and Methods; Lipid M2 in medium 
24h: Lipid M2 was added after virus adsorption to MDCK cells during the final 24 h 
virus replication incubation as described in Materials and Methods. Lipid M2 was 
used at a concentration of 4 mg/ml XPE equivalent. 
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Figure 4.12. Comparison of the chromatographic mobility of Lipid M2 and 
known fatty acids. Commercial fatty acids (30-50 nmol) were applied to analytical 
TLC plates as described in Materials and Methods. Bands were detected by primulin 
spray. 
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Figure 4.13. Comparison of lipid profiles of XPE and XGE. XPE and XGE were 
extracted and aliquots of the organic solvent phase analyzed by analytical TLC as 
described in the Materials and Methods. Bands were visualized by primulin spray. 
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Figure 4.14. Effect of human milk fractions on HPIV3 infectivity. Human milk 
was subjected to organic solvent extraction and the effect of various concentrations of 
the aqueous, organic, and whole (un-extracted) milk fractions on H1N1 virus 
infectivity was measured using the direct virus infectivity inhibition assay as 
described in Materials and Methods. (), aqueous phase; (), organic phase, (), 
intact milk.  
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Column No 1 2 3 4 5 
Virus binding at 4 C 30min Y N N N N 
Virus entry at 35 C 30min N Y N Y N 
Virus replication 24h N N Y Y N 
 
Figure 4.15. Effect of Lipid M2 on H1N1 Binding to MDCK cells. The effect of 
different lipid M2 treatment conditions (as denoted in the table above) on virus 
infectivity of MDCK cells was measured using the indirect virus infectivity inhibitory 
assay as described in Materials and Methods, except this virus binding was performed 
at 4 C rather than 35 C. Virus binding at 4 C: H1N1 virus was added to MDCK cells 
and incubated at 4 C for 30 min; Virus entry at 35 C 30min: MDCK monolayers were 
washed twice with cold PBS and then XPE was added to MDCK cells, incubated at 
35 C for 30 min; Virus replication 24h: Lipid M2 was added after virus adsorption to 
MDCK cells during the final 24 h virus replication incubation. 
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Concentration for 50% Inhibition of Infectivity 
Inhibitors Concentration 
GOS ~ 50 mg/ml* 
FOS +NI 
LNY > 10 mg/ml 
6-SL 10 mg/ml 
2-FL ~ 7.5 mg/ml 
3-SL ~ 5 mg/ml 
3-FL ~ 5 mg/ml 
SA ~ 7.5 mg/ml 
* wet weight, +NI= no inhibition  
 
Table 4.1. Summary of effect of selected oligosaccharides on in vitro H1N1 
infectivity. The relative inhibitory effects of various HMO and prebiotic 
oligosaccharides on H1N1 infectivity were evaluated by comparison of their IC50 
values. Each oligosaccharide was tested in duplicate at various concentrations ranging 
from 0.01 to 10 mg/ml as described in Materials and Methods. 
 
  
70 
Concentration for 50% Inhibition of Infectivity 
Inhibitor Concentration 
XAD 15.63 mg/ml 
XPE 0.98 mg/ml 
XGE 7.81 mg/ml 
XHE +NI 
XCE 4.59 mg/ml 
Human Milk 1.95 mg/ml 
* wet weight, +NI= no inhibition  
 
Table 4.2. Summary of effect of various infant formulas and human milk on 
H1N1 infectivity. The relative inhibitory effects of infant formulas and human milk 
on H1N1 infectivity were evaluated by comparison of their IC50 values. Each inhibitor 
was tested in duplicate at various concentrations to determine IC50 values as described 
in Materials and Methods. 
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Sample 
Protein composition (per 
100ml) 
Fat composition (per 100ml) 
XPE 1.5g hydrolyzed  whey protein 
2.17g triglycerides +1.84g 
predigested fat 
XHE 1.5g hydrolyzed whey protein None 
XGE 1.5g  hydrolyzed whey protein 
3.6 g  hydrolyzed whey protein 
No monoglycerides or lecithin 
 
Table 4.3. Comparison of the protein and lipid composition of XPE, XHE and 
XGE. Note: XHE contains only a protein component. 
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  N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Minimum Maximum 
          
Lower 
Bound 
Upper 
Bound 
    
YYY 5 1.18 0.0643 0.0287 1.1 1.26 1.12 1.25 
YNY 4 36.5 6.69 3.34 26.8 40.1 27.5 42 
NYY 4 1.2 0.075 0.0375 1.08 1.32 1.12 1.3 
YYN 5 1.81 0.0986 0.0441 1.69 1.93 1.74 1.98 
YNN 5 80.6 18 8.07 58.2 103 65.6 112 
NNY 5 38.4 9.05 4.52 28.3 46.7 26.7 46.8 
NYN 5 2.81 0.324 0.145 2.4 3.21 2.42 3.23 
NNN 5 100 19.1 8.52 76.3 124 82 125 
Total 38 40.8 45.6 7.39 25.8 55.8 1.12 125 
 
Table 4.4. Descriptive Statistics for the effect of different XPE treatment 
conditions of MDCK Cells on H1N1 infectivity. FFU means, standard deviation, 
and 95% confidence intervals for means were calculated by SPSS. N: sample size; 
Std.: standard deviation. 
 
 
 
 
 
 
Table 4.5. One-way ANOVA test for the effect of different XPE treatment 
conditions of MDCK Cells on H1N1 infectivity. F and P (Sig.) values were 
conducted through one-way ANOVA. Sig.: significance level; df: degrees of freedom. 
 
  
  
Sum of 
Squares 
df 
Mean 
Square 
F P 
Between 
Groups 72500 
7 
10400 
71.6 0.000  
Within Groups 4340 30 145     
Total 76800 37       
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A 
(I) 
Treatment 
(J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
YYY YNY -27.3 8.07 0.056 -55 0.35 
  NYY -0.0215 8.07 1 -27.7 27.6 
  YYN -0.636 7.61 1 -26.7 25.4 
  YNN -79.4 7.61 0 -105 -53.3 
  NNY -38.8 7.61 0 -24.9 -46.7 
  NYN -1.63 7.61 1 -27.7 24.4 
  NNN -98.8 7.61 0 -125 -72.7 
YNY YYY 27.3 8.07 0.056 -0.35 55 
  NYY 27.3 8.5 0.089 -1.87 56.4 
  YYN 26.7 8.07 0.069 -0.986 54.3 
  YNN -52.1 8.07 0 -79.8 -24.4 
  NNY -71.5 8.07 0 -99.2 -43.9 
  NYN 25.7 8.07 0.095 -1.98 53.3 
  NNN -71.5 8.07 0 -99.2 -43.9 
NYY YYY 0.0215 8.07 1 -27.6 27.7 
  YNY -27.3 8.5 0.089 -56.4 1.87 
  YYN -0.615 8.07 1 -28.3 27 
  YNN -79.4 8.07 0 -107 -51.7 
  NNY -98.8 8.07 0 -126 -71.1 
  NYN -1.61 8.07 1 -29.3 26.1 
  NNN -98.8 8.07 0 -126 -71.1 
YYN YYY 0.636 7.61 1 -25.4 26.7 
  YNY -26.7 8.07 0.069 -54.3 0.986 
  NYY 0.615 8.07 1 -27 28.3 
  YNN -78.8 7.61 0 -105 -52.7 
  NNY -98.2 7.61 0 -124 -72.1 
  NYN -27.3 8.07 1 -55 0.35 
  NNN -0.0215 8.07 0 -27.7 27.6 
 
Table 4.6 (cont. on next page) 
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B 
(I) 
Treatment 
(J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
YNN YYY 79.4 7.61 0.000  53.3 105 
  YNY 52.1 8.07 0.000  24.4 79.8 
  NYY 79.4 8.07 0.000  51.7 107 
  YYN 78.8 7.61 0.000  52.7 105 
  NNY -19.4 7.61 0.449  -45.5 6.66 
  NYN 77.8 7.61 0.000  51.7 104 
  NNN -19.4 7.61 0.449  -45.5 6.66 
NNY YYY 98.8 7.61 0.000  72.7 125 
  YNY 71.5 8.07 0.000  43.9 99.2 
  NYY 98.8 8.07 0.000  71.1 126 
  YYN 98.2 7.61 0.000  72.1 124 
  YNN 19.4 7.61 0.449  -6.66 45.5 
  NYN 97.2 7.61 0.000  71.1 123 
  NNN 0 7.61 1.000  -26.1 26.1 
NYN YYY 1.63 7.61 1.000  -24.4 27.7 
  YNY -25.7 8.07 0.095  -53.3 1.98 
  NYY 1.61 8.07 1.000  -26.1 29.3 
  YYN 0.994 7.61 1.000  -25.1 27.1 
  YNN -77.8 7.61 0.000  -104 -51.7 
  NNY -97.2 7.61 0.000  -123 -71.1 
  NNN -97.2 7.61 0.000  -123 -71.1 
NNN YYY 98.8 7.61 0.000  72.7 125 
  YNY 71.5 8.07 0.000  43.9 99.2 
  NYY 98.8 8.07 0.000  71.1 126 
  YYN 98.2 7.61 0.000  72.1 124 
  YNN 19.4 7.61 0.449  -6.66 45.5 
  NNY 0 7.61 1.000  -26.1 26.1 
  NYN 97.2 7.61 0.000  71.1 123 
*. The mean difference is significant at the 0.05 level. 
 
Table 4.6. Bonferroni’s post hoc test for the effect of different XPE treatment 
conditions of MDCK Cells on H1N1 infectivity. Bonferroni’s post hoc test was 
conducted to compare difference between each treatment condition. P (Sig).: 
significance level; df: degrees of freedom. For ease of reading, comparison of the 
eight different treatment groups are presented in two sets of four groups in tables, A 
and B. 
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A 
Dependent Variable: Viral Infectivity 
Concentration Inhibitor Mean 
Std. 
Deviation 
N 
250 mg/ml XPE 0 0 2 
  XHE 65.5 11.9 2 
  Total 32.7 38.4 4 
62.5  mg/ml XPE 0.105 0.0495 2 
  XHE 95.3 0 2 
  Total 47.7 55 4 
15.63  mg/ml XPE 3.74 0.403 2 
  XHE 91.1 7.98 2 
  Total 47.4 50.7 4 
3.91 mg/ml XPE 35.5 1.99 2 
  XHE 97.7 7.18 2 
  Total 66.6 36.1 4 
0.98 mg/ml XPE 46.8 0.75 2 
  XHE 91.9 3.19 2 
  Total 69.4 26.1 4 
0.24 mg/ml XPE 70.2 12.7 2 
  XHE 99.9 2.86 2 
  Total 85.1 18.7 4 
 
Table 4.7 (cont. on next page) 
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B 
Dependent Variable: Virus Infectivity 
Concentration Inhibitor Mean 
Std. 
Deviation 
N 
0.06 mg/ml XPE 82.6 5.88 2 
  XHE 96.7 15.4 2 
  Total 89.7 12.5 4 
  XPE 80.7 0.75 2 
0.015 mg/ml XHE 97.6 1.15 2 
  Total 89.1 9.78 4 
  XPE 84.5 4.84 2 
3.81x10-3 mg/ml XHE 100 6.84 2 
  Total 92.3 10.2 4 
  XPE 86.1 1.24 2 
9.54x10-4 mg/ml XHE 98.1 2.96 2 
  Total 92.1 7.18 4 
  XPE 49 36.1 20 
Total XHE 93.4 11.4 20 
  Total 71.2 34.7 40 
 
Table 4.7. Descriptive Statistics for the effect of various concentrations of XPE 
and XHE on H1N1 infectivity. FFU means and standard deviations were calculated 
by SPSS. N: sample size; Std.: standard deviation. 
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Dependent Variable: Inhibition 
Source 
Type III 
Sum of 
Squares 
df 
Mean 
Square 
F P 
Corrected Model 46100 19 2420 60.9 0.000  
Intercept 203000 1 203000 5100 0.000  
Concentration 17400 9 1940 48.7 0.000  
Inhibitor 19700 1 19700 495 0.000  
Concentration * Inhibitor 8970 9 997 25.1 0.000  
Error 795 20 39.8     
Total 250000 40       
Corrected Total 46800 39       
a. R Squared = .983 (Adjusted R Squared = .967)   
 
Table 4.8. Tests of Between-Subjects Effects for the effect of various 
concentrations of XPE and XHE on H1N1 infectivity. The effects of different 
inhibitors and various concentrations on H1N1 infectivity are analyzed. P (Sig).: 
significance level; df: degrees of freedom. 
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  N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Min Max 
          
Lower 
Bound 
Upper 
Bound 
    
Top 2 257 3.54 2.5 225 288 254 259 
Mid1 2 250 12 8.5 142 358 241 258 
Mid2 2 11.5 2.12 1.5 7.56 30.6 10 13 
Bot 2 234 12.7 9 120 348 225 243 
Loading 2 241 6.36 4.5 183 298 236 245 
Total 10 198 99 31.3 128 269 10 259 
 
Table 4.9. Descriptive Statistics for the effect of purified lipid fractions of XPE on 
H1N1 infectivity. FFU means, standard deviation, and 95% confidence interval for 
mean were calculated by SPSS. N: sample size; Std.: standard deviation. 
 
 
 
  
Sum of 
Squares 
df 
Mean 
Square 
F P 
Between Groups 87900 4 22000 302 87900 
Within Groups 364 5 72.8 
 
364 
Total 88300 9 
  
88300 
 
Table 4.10. One-way ANOVA test for the effect of purified lipid fractions of XPE 
on H1N1 infectivity. F and P (Sig.) value were conducted through one-way ANOVA. 
Sig.: significance level; df: degrees of freedom. 
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  N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Min Max 
          
Lower 
Bound 
Upper 
Bound 
    
YNN 6 49.6 5.77 2.36 43.5 55.6 44.6 59.5 
NYN 5 59.1 3.26 1.46 55.1 63.2 55 63.8 
NNY 4 38 2.06 1.03 34.7 41.3 35 39.4 
NYY 5 19.8 2.14 0.956 17.2 22.5 17.6 22.4 
NNN 4 95 14.7 7.35 71.6 118 73.8 108 
Total 24 51 25.1 5.13 40.4 61.6 17.6 108 
 
Table 4.11. Descriptive Statistics for Effect of Lipid M2 on H1N1 Binding to 
MDCK cells. FFU means, standard deviations, and 95% confidence intervals for 
mean were calculated by SPSS. N: sample size; Std.: standard deviation. 
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(I) 
Fraction 
(J) 
Fraction 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
Top Mid1 7 8.53 1 -33.7 47.7 
  Mid2 245 8.53 0! 204 286 
  Bot 22.5 8.53 0.461 -18.2 63.2 
  Loading 16 8.53 1 -24.7 56.7 
Mid1 Top -7 8.53 1 -47.7 33.7 
  Mid2 238 8.53 0 197 279 
  Bot 15.5 8.53 1 -25.2 56.2 
  Loading 9 8.53 1 -31.7 49.7 
Mid2 Top -245 8.53 0 -286 -204 
  Mid1 -238 8.53 0 -279 -197 
  Bot -223 8.53 0 -263 -182 
  Loading -229 8.53 0! -270 -188 
Bot Top -22.5 8.53 0.461 -63.2 18.2 
  Mid1 -15.5 8.53 1 -56.2 25.2 
  Mid2 223 8.53 0 182 263 
  Loading -6.5 8.53 1 -47.2 34.2 
Loading Top -16 8.53 1 -56.7 24.7 
  Mid1 -9 8.53 1 -49.7 31.7 
  Mid2 229 8.53 0 188 270 
  Bot 6.5 8.53 1 -34.2 47.2 
*. The mean difference is significant at the 0.05 level. 
 
Table 4.12. Bonferroni’s post hoc test for the effect of purified lipid fractions of 
XPE on H1N1 infectivity. Bonferroni’s post hoc test was conducted to compare 
difference between each treatment condition. P (Sig).: significance level; df: degrees 
of freedom. 
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  N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Min Max 
          
Lower 
Bound 
Upper 
Bound 
    
YYY 5 19.2 5.4 2.4 12.5 25.9 12 24 
YNY 5 530 73 32.8 441 620 459 630 
NYY 5 36.2 11.2 5 22.3 50 27 55 
YYN 5 36.4 2.97 1.33 32.7 40.1 32 40 
YNN 5 620 117 53 469 760 424 720 
NNY 5 650 69 31.1 560 730 540 720 
NYN 5 36 8.1 3.63 25.9 46.1 27 47 
NNN 5 740 45.5 20.4 690 800 660 770 
Total 40 333 314 49.6 232 433 12 770 
 
Table 4.13. Descriptive Statistics for effect of lipid M2 treatment conditions of 
MDCK Cells on H1N1 infectivity. FFU means, standard deviations, and 95% 
confidence intervals for mean were calculated by SPSS. N: sample size; Std.: standard 
deviation. 
 
 
  
Sum of  
Squares 
df 
Mean 
Square 
F P 
Between Groups 3730000 7 533000 162 
 Within Groups 105000 32 3290 
  Total 3840000 39 
    
Table 4.14. One-way ANOVA test for the effect of lipid M2 treatment conditions 
of MDCK Cells on H1N1 infectivity. F and P (Sig.) value were conducted through 
one-way ANOVA. Sig.: significance level; df: degrees of freedom. 
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A 
(I) 
Treatment 
(J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
YYY YNY -512 36.3 0 -636 -389 
  NYY -17 36.3 1 -141 107 
  YYN -17.2 36.3 1 -141 106 
  YNN -596 36.3 0 -720 -472 
  NNY -626 36.3 0 -750 -502 
  NYN -16.8 36.3 1 -140 107 
  NNN -723 36.3 0 -847 -600 
YNY YYY 512 36.3 0 389 636 
  NYY 495 36.3 0 372 619 
  YYN 495 36.3 0 372 619 
  YNN -83.6 36.3 0.778 -207 40 
  NNY -114 36.3 0.103 -237 9.99 
  NYN 496 36.3 0 372 619 
  NNN -211 36.3 0 -334 -87.2 
NYY YYY 17 36.3 1 -107 141 
  YNY -495 36.3 0 -619 -372 
  YYN -0.2 36.3 1 -124 123 
  YNN -579 36.3 0 -703 -455 
  NNY -609 36.3 0 -733 -485 
  NYN 0.2 36.3 1 -123 124 
  NNN -706 36.3 0 -830 -583 
YYN YYY 17.2 36.3 1 -106 141 
  YNY -495 36.3 0 -619 -372 
  NYY 0.2 36.3 1 -123 124 
  YNN -579 36.3 0 -702 -455 
  NNY -609 36.3 0 -732 -485 
  NYN 0.4 36.3 1 -123 124 
  NNN -706 36.3 0 -830 -582 
 
Table 4.15 (cont. on next page) 
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B 
(I) 
Treatment 
(J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
YNN YYY 596 36.3 0 472 720 
  YNY 83.6 36.3 0.778 -40 207 
  NYY 579 36.3 0 455 703 
  YYN 579 36.3 0 455 702 
  NNY -30 36.3 1 -154 93.6 
  NYN 579 36.3 0 456 703 
  NNN -127 36.3 0.038 -251 -3.61 
NNY YYY 626 36.3 0 502 750 
  YNY 114 36.3 0.103 -9.99 237 
  NYY 609 36.3 0 485 733 
  YYN 609 36.3 0 485 732 
  YNN 30 36.3 1 -93.6 154 
  NYN 609 36.3 0 486 733 
  NNN -97.2 36.3 0.323 -221 26.4 
NYN YYY 16.8 36.3 1 -107 140 
  YNY -496 36.3 0 -619 -372 
  NYY -0.2 36.3 1 -124 123 
  YYN -0.4 36.3 1 -124 123 
  YNN -579 36.3 0 -703 -456 
  NNY -609 36.3 0 -733 -486 
  NNN -706 36.3 0 -830 -583 
NNN YYY 723 36.3 0 600 847 
  YNY 211 36.3 0 87.2 334 
  NYY 706 36.3 0 583 830 
  YYN 706 36.3 0 582 830 
  YNN 127 36.3 0.038 3.61 251 
  NNY 97.2 36.3 0.323 -26.4 221 
  NYN 706 36.3 0 583 830 
*. The mean difference is significant at the 0.05 level.     
 
 
Table 4.15. Bonferroni’s post hoc test for the effect of lipid M2 treatment 
conditions of MDCK Cells on H1N1 infectivity. Bonferroni’s post hoc test was 
conducted to compare difference between each treatment condition. P (Sig): 
significance level; df: degrees of freedom. 
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Sum of 
Squares 
df 
Mean 
Square 
F P 
Between Groups 13600 4 3400 72.8 
 Within Groups 888 19 46.8 
  Total 14500 23 
    
Table 4.16. One-way ANOVA test for the effect of Lipid M2 on H1N1 Binding to 
MDCK cells. F and P (Sig.) value were conducted through one-way ANOVA. Sig.: 
significance level; df: degrees of freedom. 
 
 
 
 
Table 4.17. Bonferroni’s post hoc test for the effect of lipid M2 treatment 
conditions of MDCK Cells on H1N1 infectivity. Bonferroni’s post hoc test was 
conducted to compare difference between each treatment condition. P (Sig): 
significance level; df: degrees of freedom. 
(I) 
Treatment 
(J) 
Treatment 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
95% 
Confidence 
Interval 
          
Lower 
Bound 
Upper 
Bound 
YNN NYN -9.57 4.14 0.322 -22.7 3.57 
  NNY 11.6 4.41 0.169 -2.46 25.6 
  NYY 29.7 4.14 0 16.6 42.9 
  NNN -45.4 4.41 0 -59.4 -31.4 
NYN YNN 9.57 4.14 0.322 -3.57 22.7 
  NNY 21.1 4.59 0.002 6.57 35.7 
  NYY 39.3 4.32 0 25.6 53 
  NNN -35.9 4.59 0 -50.4 -21.3 
NNY YNN -11.6 4.41 0.169 -25.6 2.46 
  NYN -21.1 4.59 0.002 -35.7 -6.57 
  NYY 18.2 4.59 0.008 3.63 32.7 
  NNN -57 4.83 0 -72.3 -41.6 
NYY YNN -29.7 4.14 0 -42.9 -16.6 
  NYN -39.3 4.32 0 -53 -25.6 
  NNY -18.2 4.59 0.008 -32.7 -3.63 
  NNN -75.2 4.59 0 -89.7 -60.6 
NNN YNN 45.4 4.41 0 31.4 59.4 
  NYN 35.9 4.59 0 21.3 50.4 
  NNY 57 4.83 0 41.6 72.3 
  NYY 75.2 4.59 0 60.6 89.7 
*. The mean difference is significant at the 0.05 level. 
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CHAPTER 5: DISCUSSION 
Our investigations of natural product inhibitors of respiratory viral infection required 
the design of a screening assay to rapidly and precisely measure antiviral inhibitory 
activity in vitro.  For this purpose, indirect and direct FFU blocking assays were 
designed and performed using some modifications of a previously developed assay (J. 
K. Johnson, Schmidt, Gelberg, & Kuhlenschmidt, 2004). In the indirect blocking 
assay, inhibitors were added to host cells at different times (before, during and after 
virus adsorption) using eight different combinations. By using these different 
combinations, we are able to examine which step during the virus-host cell infection 
cycle the inhibitor blocked.  
 
The results of our initial screen, using HMO (Table 4.1), show that 3-SL and 3-FL 
may be candidate inhibitors for H1N1 infection. It is generally known that the 
infection of many bacteria and viruses occurs by binding to particular glycans on the 
surface of epithelial cells.  Some of these glycan-binding determinants are also part of 
HMO, suggesting that HMO may serve as soluble receptor analogs, block pathogen 
adhesion, and protect the breastfed infant against certain microbial infections (Kobata, 
2010). Suzuki et al. pointed out the attachment of influenza virus to epithelial cells 
occurs via a binding domain on the HA which recognizes SA containing glycans on 
the surface of epithelial cell (Y. Suzuki, 2005).   This may explain why SA, albeit it at 
relatively high concentration, can inhibit H1N1 infectivity. Thus, it is likely 3'-SL and 
3'-FL behave as soluble receptors for H1N1 attachment. Receptors on host cells and 
86 
these oligosaccharides compete for attachment by the viral binding protein (HA).  
However, considering the IC50 of 3-SL and 3-FL(~ 5mg/ml), the use of these HMO 
may not be economically feasible, especially as routine additives to infant formula. 
This result is not particularly surprising, since the affinity of soluble small 
oligosaccharides or monosaccharides for the combining site in carbohydrate binding 
proteins is generally low, typically ranging from micro- to millimolar (W. I. Weis & 
Drickamer, 1996). It is quite possible one could compensate for these weak 
monovalent interactions by coupling HMO to protein or lipid adducts to form 
neoglycoconjugates which more closely mimic the complex carbohydrate structures 
found on host cell surfaces that are exploited by many microbial pathogens.  This is 
typically achieved by assembling individual oligosaccharides into multimers, to allow 
multivalent carbohydrate binding proteins to simultaneously engage many individual 
oligosaccharides analogs (W. I. Weis & Drickamer, 1996; William I, 1997). This 
―cooperative multiplicity‖ of low affinity combining sites has the statistical effect of 
significantly increasing the avidity of carbohydrate binding proteins for their intend 
targets (Mulvey, Kitov, Marcato, Bundle, & Armstrong, 2001). While multimerization 
of oligosaccharides can overcome these weak monovalent interactions, it presents 
another problem: these synthetic multimers are no longer natural molecules. Such 
derivatives would be considered drugs rather than natural products and thus may not 
be acceptable as a routine additive to human infant formula. The safety of such new 
drugswould need to be rigorously tested before they could be added into infant food 
and may never be acceptable to consumers. 
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Following completion of the HMO screening assays, we began to search for other 
potential nutraceutical or natural product inhibitors that may possess more potent 
inhibitory activity against respiratory viruses such as H1N1.  For this purpose, we 
screened a variety of infant formulas and human milk. Among all these compounds 
tested, XGE, XPE infant formulas, and human milk were found have strong antiviral 
activity.  They were able to inhibit virus infectivity at concentrations below 8mg/ml. 
Furthermore, compared to XGE, the antiviral activities of XPE and human milk were 
remarkable anddisplayed IC50values of 0.98 mg/ml and 1.95 mg/ml respectively. In 
this regard, it is worth noting that the inhibition curve of XPE is similar to that of 
human milk. These results may suggest that both XPE and human milk contain 
similar antiviral compounds. 
 
To characterize XPE’s mechanism of inhibition, we first sought to determine if XPE 
acts on the virus or on the MDCK cell to block viral infection. Using the indirect 
blocking assay, XPE was able to at least partially block H1N1 infectivity regardless of 
whether it was added before, during and after, virus adsorption.  This result 
suggestedXPEmay act on both the virus and host cells to inhibit virus infection. It is 
worth noting that when XPE was only added to host cells prior to virus inoculation 
and then removed, or after virus adsorption was complete, virus infectivity could still 
be reduced by 81%, and 39%, respectively.  Although the most effective (>95% 
inhibition) combination was when XPE was present in all three stages of the virus 
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infection cycle (before, during, after virus adsorption), these results suggested XPE 
has the potential to protect as well as treat ongoing H1N1 infection.  
 
Based on these early promising results, we began to investigate which component of 
XPE was responsible for the antiviral activity.  XPE is composed of a fat system and a 
protein system. Compared to XPE, XHE has the same protein system but no fat 
system and displays no antiviral inhibitory activity. Accordingly, we hypothesizedthe 
fat system was responsible for the antiviral ability. The fat system and the protein 
system of XPE were separated and tested using the direct blocking assy. The results 
showed organic solvent extracts possessed a stronger antiviralactivity than intact XPE, 
while aqueous extracts contained little or no inhibitory ability. These results 
confirmed our initial speculation that the active antiviral component of XPE was 
contained in the fat system of this infant formula.  
 
To further characterize the viral inhibitory activity detected in organic solvent extracts 
of XPE, TLC was used to fractionate and analyze the organic extracts. Each separate 
fraction was purified and screened for itsantiviral activity by the direct blocking assay. 
A single band (Mid2) was found to possess almost all of the inhibitory activity of the 
entire organic extract. Furthermore, the results of indirect blocking assays showed that 
Mid2 displayed the same inhibitory characteristicsof intact XPE, which can inhibit 
virus infectivity when added before virus inoculation, and then removed or added 
after virus inoculation. These results indicate Mid2 is the active lipid, which is 
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primarily responsible for the antiviral activity of XPE.  
 
In an effort to identity the chemical nature of the Mid2,we compared the thin layer 
chromatographic mobility of Mid2 and XPE lipid extracts withseveral commercial 
lipids and fatty acids. None of these lipid standards co-chromatographed with Mid2. 
Furthermore, the organic solvent extract of XGE, which has the same protein system 
as XPE but lacks its predigested fat component and antiviral activity, was analyzed by 
TLC. Although this comparison of the lipid profile of XPE and XGE clearly indicated 
Mid2 originated from the predigested fat component of XPE, the exact chemical 
identify of Mid2 lipid has yet to be determined. In addition, organic solvent extraction 
of human milk, using the same procedure as for XPE,demonstrated the antiviral 
activity of human milk was recovered in lipid fraction and contains a lipid band 
displaying similar TLC mobility as observed for Mid2.  Whether these two lipids have 
similar structure has yet to be determined.  Nevertheless, these results demonstrate 
specific milk and infant formula derived lipids possess antiviral activity. 
 
To begin to address the mechanism by which Mid2 or milk derived lipids block virus 
infection, we tested whether Mid2 acts solely by blocking virus attachment to host 
cells or if it can also interfere with virus entry into the cell.  For these experiments, the 
blocking assay was performed in the presence and absence of Mid2 by first allowing 
viral attachment at 4 C. Under this condition, virus can only attach to but not enter the 
cell. Following adsorption, the cells were washed free of unbound virus and then the 
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temperature was raised to 37 C to allow virus entry.  The result of these experiments 
indicated Mid2 or XPE inhibited virus infectivity by approximately 50% when added 
during the 4 C virus attachment stage as compared to 96% inhibition when added 
during 37 C incubations.  Addition of Mid2 only during the viral entry stage 
(aftervirus adsorption at 4 C, washing to remove unbound virus, and then adding 
Mid2 followed by warming to 37 C) resulted in approximately a 40-45% inhibition of 
virus infectivity.  The combined inhibitory effect of Mid2 on both virus attachment 
and entry is approximately 90-95% which agrees closely with the amount of 
inhibition (~96%) seen when either Mid2 or XPE is added at 37 C at the beginning of 
virus infectivity (when virus, cells and inhibitor or added at the same time at 37 C).  
These results strongly suggest Mid2 blocks not only virus attachment but alsovirus 
entry. 
 
Previously reported studies also have indicated human milk lipids can inhibit the 
infectivity of enveloped viruses. Halldor et al. concluded that antiviral activity was 
found in storage milk (Thormar, Isaacs, Brown, Barshatzky, & Pessolano, 1987). 
Isaacs et al. found that fresh milk treated with antibody to secretory IgA did not 
inhibit virus but became antiviral effect after 1h in the stomachs of suckling infants (C. 
E. Isaacs, Thormar, & Pessolano, 1986). Subsequent studiesfrom this same group 
indicated the occurrence of antiviral activity depended on the release of free fatty 
acids by milk lipases (Thormar, et al, 1994). These authors concluded that milk-
derived antiviral fatty acids were found to affect the viral envelope, causing leakage 
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and, at higher concentrations, a complete disintegration of the envelope and the viral 
particles and suggested that lipids commonly found in natural products could possibly 
be used as antiviral agents against enveloped viruses.Sakar et al also observed the 
cream fraction of human milk was able to effect degradation of the viral envelope of 
mammary tumor virus (N. H. Sarkar, Charney, Dion, & Moore, 1973). The lowest 
concentration of Mid2 causing >90% inhibition of virus activity in our studies was 
approximately 50 µM (0.015 mg/ml XPE equivalents assuming 50% the lipid in XPE 
is Mid2 and assuming it is a fatty acid with an average molecular weight of ~300. 
Although, this concentration is far below (nearly 3 orders of magnitude) the 
concentration (2-20 mM) used in the studies mentioned above (Thormar, et al, 1994), 
where a direct effect on virus envelop integrity was observed, we can not rule out the 
possibility of a direct effect of lipid Mid2 on H1N1 envelope structure. Although the 
exact mechanism of action of lipid Mid2 is not clear, andeven though it has been 
suggested that the fatty acids or their monoesters might be incorporated into the lipid 
membrane, causing disruption of viral envelopes (Cullis & Hope, 1978), it is also 
possible, given the relative low concentration of lipid Mid2 necessary for antiviral 
activity, that other more complex mechanisms, such as interference with signal 
transduction, may be operative in the case of Mid2.  
 
In sum, we have shown that a predigested lipid, which may also exist in human milk, 
strongly inhibits H1N1 infectivity in vitro. Continued purification of the active lipid 
from XPE infant formula and human milk, followed by further chemical 
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characterization studies, as well as determination of its exact mechanism of inhibition 
of H1N1 infectivity, may ultimately provide an avenue for its use as a natural 
therapeutic or prophylactic nutriceutical to reduce respiratory virus infection in infants. 
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CHAPTER 6: CONCLUSION 
This study was undertaken to experimentally address the hypothesis that bioactive 
natural products, such as those found in commercial infant formula or human milk, 
can function as antiviral nutriceuticals for the treatment or prevention of respiratory 
disease in infants and young children.  The hypothesis was tested by screening the 
antiviral effect of some known antimicrobial compounds, such as oligosaccharides 
and lipids present in human milk and certain infant formulas, for their ability to 
inhibit respiratory virus infectivity in vitro. The results of the initial screening 
experiments demonstrated certain oligosaccharides, 3'-SL and 3'-FL, found in human 
milk and a lipid fraction extracted from selected commercial infant formula, possess 
antiviral activity.  Although 3'-SL and 3'-FL possess antiviral activity, a comparison of 
their IC50 values reveals effective inhibition requires mg/ml concentration, a range that 
may not be economically feasible for routine inclusion as antiviral nutriceutical 
compounds in infant formula.   
 
On the other hand, a remarkable antiviral activity was found in one of the infant 
formula (XPE) tested. Further investigation revealed a lipid fraction (Mid2) is 
primarily responsible for the antiviral ability of XPE. The purified Mid2 displays 
greater anti-viral specific activity than crude XPE. Furthermore, an appealing 
characteristic of mid2 is that when MDCK cells are pretreated with Mid2 followed by 
removal of Mid2 before virus adsorption, or if Mid2 is added to cells after virus 
adsorption, virus infectivity is still inhibited. While the complete chemical 
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characterization of Mid2 is not completed, we suspect this lipid is fatty acid derived 
froma predigested fat component present in XPE. We also believe this or similar lipid 
is present in human milk based our preliminary fractionation results. Further analysis 
such as Fast Atom Bombardment Mass Spectrometry (FAB-MS) and NMR is 
underway and should help to identify the exact chemical structure of lipid Mid2. The 
exact mechanism of Mid2 antiviral activity also is not clear.  It is possible lipid Mid2 
could be incorporated into the host cell membrane and cause destabilization of the 
bilayer via a detergent-like effect. Such a mechanism might also lead to the disruption 
of the integrityor the viral envelop.  Although we have not systematically tested this 
possibility, the concentrations of lipid Mid2 capable of inhibiting >90% of virus 
infectivity caused no obvious CPE or damage to host cell monolayers.  Accordingly, a 
likely alternative hypothesis for the mechanism of action of lipid Mid2 is that it 
specifically binds to the H1N1 envelope and competes with virus-host cell binding 
receptors.  This virus binding mechanism coupled with uptake of exogenous lipid 
Mid2 by host cells could explain why lipid Mid2 is active not only during virus-host 
cell binding and entry but also during virus replication/maturation. 
 
In summary, the results of this study illustrate the potential value of selected natural 
products, such as human milk-derived lipids and oligosaccharides, for use as 
nutriceuticals in prevention or therapy of viral respiratory diseases in infants and 
young children. In particular, the use of such bioactive nutriceutical compounds, such 
as lipid Mid2, may help augment or overcome the limitations of current antivirals, the 
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unavailability of effective vaccines for respiratory viral diseases, and the immaturity 
of infant immune system. 
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